

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark  
Office  
(Box PCT)  
Crystal Plaza 2  
Washington, DC 20231  
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 24 June 1999 (24.06.99)	
International application No. PCT/CA98/01059	Applicant's or agent's file reference 1770-183PCT
International filing date (day/month/year) 12 November 1998 (12.11.98)	Priority date (day/month/year) 12 November 1997 (12.11.97)
Applicant SZYF, Moshe et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

07 June 1999 (07.06.99)

☐ in a notice effecting later election filed with the International Bureau on:
2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer S. Mafla Telephone No.: (41-22) 338.83.38
---	--

From the INTERNATIONAL BUREAU

PCT

**NOTICE INFORMING THE APPLICANT OF THE  
COMMUNICATION OF THE INTERNATIONAL  
APPLICATION TO THE DESIGNATED OFFICES**

(PCT Rule 47.1(c), first sentence)

To:

CÔTÉ, France  
Swabey Ogilvy Renault  
Suite 1600  
1981 McGill College Avenue  
Montréal, Québec H3A 2Y3  
CANADA

SWABEY OGILVY RENAULT  
MCGILL COLLEGE  
RECEIVED  
JUN 6 1999  
218/916/11/12/13/14/15/16/17/18/19/20/21/22/23/24/25/26/27/28/29/30/31/32/33/34/35/36/37/38/39/40/41/42/43/44/45/46/47/48/49/50/51/52/53/54/55/56/57/58/59/60/61/62/63/64/65/66/67/68/69/70/71/72/73/74/75/76/77/78/79/80/81/82/83/84/85/86/87/88/89/90/91/92/93/94/95/96/97/98/99/100/101/102/103/104/105/106/107/108/109/110/111/112/113/114/115/116/117/118/119/120/121/122/123/124/125/126/127/128/129/130/131/132/133/134/135/136/137/138/139/140/141/142/143/144/145/146/147/148/149/150/151/152/153/154/155/156/157/158/159/160/161/162/163/164/165/166/167/168/169/170/171/172/173/174/175/176/177/178/179/180/181/182/183/184/185/186/187/188/189/190/191/192/193/194/195/196/197/198/199/200/201/202/203/204/205/206/207/208/209/210/211/212/213/214/215/216/217/218/219/220/221/222/223/224/225/226/227/228/229/230/231/232/233/234/235/236/237/238/239/240/241/242/243/244/245/246/247/248/249/250/251/252/253/254/255/256/257/258/259/260/261/262/263/264/265/266/267/268/269/270/271/272/273/274/275/276/277/278/279/280/281/282/283/284/285/286/287/288/289/290/291/292/293/294/295/296/297/298/299/300/301/302/303/304/305/306/307/308/309/310/311/312/313/314/315/316/317/318/319/320/321/322/323/324/325/326/327/328/329/330/331/332/333/334/335/336/337/338/339/340/341/342/343/344/345/346/347/348/349/350/351/352/353/354/355/356/357/358/359/360/361/362/363/364/365/366/367/368/369/370/371/372/373/374/375/376/377/378/379/380/381/382/383/384/385/386/387/388/389/390/391/392/393/394/395/396/397/398/399/400/401/402/403/404/405/406/407/408/409/410/411/412/413/414/415/416/417/418/419/420/421/422/423/424/425/426/427/428/429/430/431/432/433/434/435/436/437/438/439/440/441/442/443/444/445/446/447/448/449/450/451/452/453/454/455/456/457/458/459/460/461/462/463/464/465/466/467/468/469/470/471/472/473/474/475/476/477/478/479/480/481/482/483/484/485/486/487/488/489/490/491/492/493/494/495/496/497/498/499/500/501/502/503/504/505/506/507/508/509/510/511/512/513/514/515/516/517/518/519/520/521/522/523/524/525/526/527/528/529/530/531/532/533/534/535/536/537/538/539/540/541/542/543/544/545/546/547/548/549/550/551/552/553/554/555/556/557/558/559/560/561/562/563/564/565/566/567/568/569/570/571/572/573/574/575/576/577/578/579/580/581/582/583/584/585/586/587/588/589/590/591/592/593/594/595/596/597/598/599/600/601/602/603/604/605/606/607/608/609/610/611/612/613/614/615/616/617/618/619/620/621/622/623/624/625/626/627/628/629/630/631/632/633/634/635/636/637/638/639/640/641/642/643/644/645/646/647/648/649/650/651/652/653/654/655/656/657/658/659/660/661/662/663/664/665/666/667/668/669/670/671/672/673/674/675/676/677/678/679/680/681/682/683/684/685/686/687/688/689/690/691/692/693/694/695/696/697/698/699/700/701/702/703/704/705/706/707/708/709/710/711/712/713/714/715/716/717/718/719/720/721/722/723/724/725/726/727/728/729/730/731/732/733/734/735/736/737/738/739/740/741/742/743/744/745/746/747/748/749/750/751/752/753/754/755/756/757/758/759/760/761/762/763/764/765/766/767/768/769/770/771/772/773/774/775/776/777/778/779/780/781/782/783/784/785/786/787/788/789/790/791/792/793/794/795/796/797/798/799/800/801/802/803/804/805/806/807/808/809/810/811/812/813/814/815/816/817/818/819/820/821/822/823/824/825/826/827/828/829/830/831/832/833/834/835/836/837/838/839/840/841/842/843/844/845/846/847/848/849/850/851/852/853/854/855/856/857/858/859/860/861/862/863/864/865/866/867/868/869/870/871/872/873/874/875/876/877/878/879/880/881/882/883/884/885/886/887/888/889/890/891/892/893/894/895/896/897/898/899/900/901/902/903/904/905/906/907/908/909/910/911/912/913/914/915/916/917/918/919/920/921/922/923/924/925/926/927/928/929/930/931/932/933/934/935/936/937/938/939/940/941/942/943/944/945/946/947/948/949/950/951/952/953/954/955/956/957/958/959/960/961/962/963/964/965/966/967/968/969/970/971/972/973/974/975/976/977/978/979/980/981/982/983/984/985/986/987/988/989/990/991/992/993/994/995/996/997/998/999/1000/1001/1002/1003/1004/1005/1006/1007/1008/1009/1010/1011/1012/1013/1014/1015/1016/1017/1018/1019/1020/1021/1022/1023/1024/1025/1026/1027/1028/1029/1030/1031/1032/1033/1034/1035/1036/1037/1038/1039/1040/1041/1042/1043/1044/1045/1046/1047/1048/1049/1050/1051/1052/1053/1054/1055/1056/1057/1058/1059/1060/1061/1062/1063/1064/1065/1066/1067/1068/1069/1070/1071/1072/1073/1074/1075/1076/1077/1078/1079/1080/1081/1082/1083/1084/1085/1086/1087/1088/1089/1090/1091/1092/1093/1094/1095/1096/1097/1098/1099/1100/1101/1102/1103/1104/1105/1106/1107/1108/1109/1110/1111/1112/1113/1114/1115/1116/1117/1118/1119/1120/1121/1122/1123/1124/1125/1126/1127/1128/1129/1130/1131/1132/1133/1134/1135/1136/1137/1138/1139/1140/1141/1142/1143/1144/1145/1146/1147/1148/1149/1150/1151/1152/1153/1154/1155/1156/1157/1158/1159/1160/1161/1162/1163/1164/1165/1166/1167/1168/1169/1170/1171/1172/1173/1174/1175/1176/1177/1178/1179/1180/1181/1182/1183/1184/1185/1186/1187/1188/1189/1190/1191/1192/1193/1194/1195/1196/1197/1198/1199/1200/1201/1202/1203/1204/1205/1206/1207/1208/1209/1210/1211/1212/1213/1214/1215/1216/1217/1218/1219/1220/1221/1222/1223/1224/1225/1226/1227/1228/1229/1230/1231/1232/1233/1234/1235/1236/1237/1238/1239/1240/1241/1242/1243/1244/1245/1246/1247/1248/1249/1250/1251/1252/1253/1254/1255/1256/1257/1258/1259/1260/1261/1262/1263/1264/1265/1266/1267/1268/1269/1270/1271/1272/1273/1274/1275/1276/1277/1278/1279/1280/1281/1282/1283/1284/1285/1286/1287/1288/1289/1290/1291/1292/1293/1294/1295/1296/1297/1298/1299/1300/1301/1302/1303/1304/1305/1306/1307/1308/1309/1310/1311/1312/1313/1314/1315/1316/1317/1318/1319/1320/1321/1322/1323/1324/1325/1326/1327/1328/1329/1330/1331/1332/1333/1334/1335/1336/1337/1338/1339/1340/1341/1342/1343/1344/1345/1346/1347/1348/1349/1350/1351/1352/1353/1354/1355/1356/1357/1358/1359/1360/1361/1362/1363/1364/1365/1366/1367/1368/1369/1370/1371/1372/1373/1374/1375/1376/1377/1378/1379/1380/1381/1382/1383/1384/1385/1386/1387/1388/1389/1390/1391/1392/1393/1394/1395/1396/1397/1398/1399/1400/1401/1402/1403/1404/1405/1406/1407/1408/1409/1410/1411/1412/1413/1414/1415/1416/1417/1418/1419/1420/1421/1422/1423/1424/1425/1426/1427/1428/1429/1430/1431/1432/1433/1434/1435/1436/1437/1438/1439/1440/1441/1442/1443/1444/1445/1446/1447/1448/1449/1450/1451/1452/1453/1454/1455/1456/1457/1458/1459/1460/1461/1462/1463/1464/1465/1466/1467/1468/1469/1470/1471/1472/1473/1474/1475/1476/1477/1478/1479/1480/1481/1482/1483/1484/1485/1486/1487/1488/1489/1490/1491/1492/1493/1494/1495/1496/1497/1498/1499/1500/1501/1502/1503/1504/1505/1506/1507/1508/1509/1510/1511/1512/1513/1514/1515/1516/1517/1518/1519/1520/1521/1522/1523/1524/1525/1526/1527/1528/1529/1530/1531/1532/1533/1534/1535/1536/1537/1538/1539/1540/1541/1542/1543/1544/1545/1546/1547/1548/1549/1550/1551/1552/1553/1554/1555/1556/1557/1558/1559/1560/1561/1562/1563/1564/1565/1566/1567/1568/1569/1570/1571/1572/1573/1574/1575/1576/1577/1578/1579/1580/1581/1582/1583/1584/1585/1586/1587/1588/1589/1590/1591/1592/1593/1594/1595/1596/1597/1598/1599/1600/1601/1602/1603/1604/1605/1606/1607/1608/1609/1610/1611/1612/1613/1614/1615/1616/1617/1618/1619/1620/1621/1622/1623/1624/1625/1626/1627/1628/1629/1630/1631/1632/1633/1634/1635/1636/1637/1638/1639/1640/1641/1642/1643/1644/1645/1646/1647/1648/1649/1650/1651/1652/1653/1654/1655/1656/1657/1658/1659/1660/1661/1662/1663/1664/1665/1666/1667/1668/1669/1670/1671/1672/1673/1674/1675/1676/1677/1678/1679/1680/1681/1682/1683/1684/1685/1686/1687/1688/1689/1690/1691/1692/1693/1694/1695/1696/1697/1698/1699/1700/1701/1702/1703/1704/1705/1706/1707/1708/1709/1710/1711/1712/1713/1714/1715/1716/1717/1718/1719/1720/1721/1722/1723/1724/1725/1726/1727/1728/1729/1730/1731/1732/1733/1734/1735/1736/1737/1738/1739/1740/1741/1742/1743/1744/1745/1746/1747/1748/1749/1750/1751/1752/1753/1754/1755/1756/1757/1758/1759/1760/1761/1762/1763/1764/1765/1766/1767/1768/1769/1770/1771/1772/1773/1774/1775/1776/1777/1778/1779/1780/1781/1782/1783/1784/1785/1786/1787/1788/1789/1790/1791/1792/1793/1794/1795/1796/1797/1798/1799/1800/1801/1802/1803/1804/1805/1806/1807/1808/1809/1810/1811/1812/1813/1814/1815/1816/1817/1818/1819/1820/1821/1822/1823/1824/1825/1826/1827/1828/1829/1830/1831/1832/1833/1834/1835/1836/1837/1838/1839/1840/1841/1842/1843/1844/1845/1846/1847/1848/1849/1850/1851/1852/1853/1854/1855/1856/1857/1858/1859/1860/1861/1862/1863/1864/1865/1866/1867/1868/1869/1870/1871/1872/1873/1874/1875/1876/1877/1878/1879/1880/1881/1882/1883/1884/1885/1886/1887/1888/1889/1890/1891/1892/1893/1894/1895/1896/1897/1898/1899/1900/1901/1902/1903/1904/1905/1906/1907/1908/1909/1910/1911/1912/1913/1914/1915/1916/1917/1918/1919/1920/1921/1922/1923/1924/1925/1926/1927/1928/1929/1930/1931/1932/1933/1934/1935/1936/1937/1938/1939/1940/1941/1942/1943/1944/1945/1946/1947/1948/1949/1950/1951/1952/1953/1954/1955/1956/1957/1958/1959/1960/1961/1962/1963/1964/1965/1966/1967/1968/1969/1970/1971/1972/1973/1974/1975/1976/1977/1978/1979/1980/1981/1982/1983/1984/1985/1986/1987/1988/1989/1990/1991/1992/1993/1994/1995/1996/1997/1998/1999/2000/2001/2002/2003/2004/2005/2006/2007/2008/2009/2010/2011/2012/2013/2014/2015/2016/2017/2018/2019/2020/2021/2022/2023/2024/2025/2026/2027/2028/2029/2030/2031/2032/2033/2034/2035/2036/2037/2038/2039/2040/2041/2042/2043/2044/2045/2046/2047/2048/2049/2050/2051/2052/2053/2054/2055/2056/2057/2058/2059/2060/2061/2062/2063/2064/2065/2066/2067/2068/2069/2070/2071/2072/2073/2074/2075/2076/2077/2078/2079/2080/2081/2082/2083/2084/2085/2086/2087/2088/2089/2090/2091/2092/2093/2094/2095/2096/2097/2098/2099/2100/2101/2102/2103/2104/2105/2106/2107/2108/2109/2110/2111/2112/2113/2114/2115/2116/2117/2118/2119/2120/2121/2122/2123/2124/2125/2126/2127/2128/2129/2130/2131/2132/2133/2134/2135/2136/2137/2138/2139/2140/2141/2142/2143/2144/2145/2146/2147/2148/2149/2150/2151/2152/2153/2154/2155/2156/2157/2158/2159/2160/2161/2162/2163/2164/2165/2166/2167/2168/2169/2170/2171/2172/2173/2174/2175/2176/2177/2178/2179/2180/2181/2182/2183/2184/2185/2186/2187/2188/2189/2190/2191/2192/2193/2194/2195/2196/2197/2198/2199/2200/2201/2202/2203/2204/2205/2206/2207/2208/2209/2210/2211/2212/2213/2214/2215/2216/2217/2218/2219/2220/2221/2222/2223/2224/2225/2226/2227/2228/2229/2230/2231/2232/2233/2234/2235/2236/2237/2238/2239/2240/2241/2242/2243/2244/2245/2246/2247/2248/2249/2250/2251/2252/2253/2254/2255/2256/2257/2258/2259/2260/2261/2262/2263/2264/2265/2266/2267/2268/2269/2270/2271/2272/2273/2274/2275/2276/2277/2278/2279/2280/2281/2282/2283/2284/2285/2286/2287/2288/2289/2290/2291/2292/2293/2294/2295/2296/2297/2298/2299/2300/2301/2302/2303/2304/2305/2306/2307/2308/2309/2310/2311/2312/2313/2314/2315/2316/2317/2318/2319/2320/2321/2322/2323/2324/2325/2326/2327/2328/2329/2330/2331/2332/2333/2334/2335/2336/2337/2338/2339/2340/2341/2342/2343/2344/2345/2346/2347/2348/2349/2350/2351/2352/2353/2354/2355/2356/2357/2358/2359/2360/2361/2362/2363/2364/2365/2366/2367/2368/2369/2370/2371/2372/2373/2374/2375/2376/2377/2378/2379/2380/2381/2382/2383/2384/2385/2386/2387/2388/2389/2390/2391/2392/2393/2394/2395/2396/2397/2398/2399/2400/2401/2402/2403/2404/2405/2406/2407/2408/2409/2410/2411/2412/2413/2414/2415/2416/2417/2418/2419/2420/2421/2422/2423/2424/2425/2426/2427/2428/2429/2430/2431/2432/2433/2434/2435/2436/2437/2438/2439/2440/2441/2442/2443/2444/2445/2446/2447/2448/2449/2450/2451/2452/2453/2454/2455/2456/2457/2458/2459/2460/2461/2462/2463/2464/2465/2466/2467/2468/2469/2470/2471/2472/2473/2474/2475/2476/2477/2478/2479/2480/2481/2482/2483/2484/2485/2486/2487/2488/2489/2490/2491/2492/2493/2494/2495/2496/2497/2498/2499/2500/2501/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/2513/2514/2515/2516/2517/2518/2519/2520/2521/2522/2523/2524/2525/2526/2527/2528/2529/2530/2531/2532/2533/2534/2535/2536/2537/2538/2539/2540/2541/2542/2543/2544/2545/2546/2547/2548/2549/2550/2551/2552/2553/2554/2555/2556/2557/2558/2559/2560/2561/2562/2563/2564/2565/2566/2567/2568/2569/2570/2571/2572/2573/2574/2575/2576/2577/2578/2579/2580/2581/2582/2583/2584/2585/2586/2587/2588/2589/2590/2591/2592/2593/2594/2595/2596/2597/2598/2599/2600/2601/2602/2603/2604/2605/2606/2607/2608/2609/2

09/554414

**NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF  
THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES**

<b>Date of mailing (day/month/year)</b> 20 May 1999 (20.05.99)	<b>IMPORTANT NOTICE</b>
<b>Applicant's or agent's file reference</b> 1770-183PCT	<b>International application No.</b> PCT/CA98/01059
<p>The applicant is hereby notified that, at the time of establishment of this Notice, the time limit under Rule 46.1 for making amendments under Article 19 has not yet expired and the International Bureau had received neither such amendments nor a declaration that the applicant does not wish to make amendments.</p>	



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : C12N 15/52, 9/00, A61K 38/43, C07K 16/40, C12N 15/11, A61K 48/00, G01N 33/50</p>	<p>A1</p>	<p>(11) International Publication Number: <b>WO 99/24583</b> (43) International Publication Date: 20 May 1999 (20.05.99)</p>
<p>(21) International Application Number: PCT/CA98/01059 (22) International Filing Date: 12 November 1998 (12.11.98) (30) Priority Data: 2,220,805 12 November 1997 (12.11.97) CA 2,230,991 11 May 1998 (11.05.98) CA (71) Applicant (for all designated States except US): MCGILL UNIVERSITY [CA/CA]; 845 Sherbrooke Street West, Montréal, Québec H3A 2T5 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): SZYF, Moshe [CA/CA]; 7522 Wavell, Côte Saint-Luc, Québec H4W 2L7 (CA). BHATTACHARYA, Sanjoy [IN/CA]; Apartment 1403, 2150 Mackay Street, Montréal, Québec H3G 2M2 (CA). RAMCHANDAN, Shyam [CA/CA]; 5843 Hillcrest Crescent, Niagara Falls, Ontario L2J 2A8 (CA). (74) Agents: CÔTÉ, France et al.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: DNA DEMETHYLASE, THERAPEUTIC AND DIAGNOSTIC USES THEREOF (57) Abstract The present invention relates to a DNA demethylase enzyme having about 40 KDa, and wherein said DNA demethylase enzyme is overexpressed in cancer cells and not in normal cells. The present invention also relates to the therapeutic and diagnostic uses of the DNA demethylase.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**DNA DEMETHYLASE, THERAPEUTIC AND  
DIAGNOSTIC USES THEREOF**

**BACKGROUND OF THE INVENTION**

5 (a) Field of the Invention

The invention relates to a novel enzyme, DNA demethylase, therapeutic and diagnostic uses thereof.

(b) Description of Prior Art

Many lines of evidence have established that  
10 modification of cytosine moieties residing in the dinucleotide sequence CpG in vertebrate genomes is involved in regulating a number of genome functions such as parental imprinting, X-inactivation, suppression of methylation of ectopic genes and differential gene  
15 expression (Szyf, M. (1996) Pharmacol. Ther. 70, 1-37). DNA methylation performs its function of differentially marking genes because the distribution of methylated CpGs is tissue- and site- specific forming a pattern of methylation (Szyf, M. (1996) Pharmacol. Ther. 70, 1-  
20 37). It is clear that the pattern of methylation is fashioned by a sequence of methylation and demethylation events (Brandeis, M. et al. (1993) Bioassays 15, 709-713) during development and is maintained in the fully differentiated cell (Razin, A. et al. (1980) Sci-  
25 ence 210, 604-610). While it was originally suggested that DNA demethylation is accomplished by a passive loss of methyl groups during replication (Razin, A. et al. (1980) Science 210, 604-610), it is now clear that an active process of demethylation occurs in embryonal  
30 cells (Frank, D. et al. (1991) Nature 351, 239-241), in differentiating cell lines (Razin, A. et al. (1986) Proc. Natl. Acad. Sci. USA 83, 2827-2831; Szyf, M. et al. (1985) Proc. Natl. Acad. Sci. USA 82, 8090-8094) and in response to estrogen treatment (Saluz, H.P. et  
35 al. (1986) Proc. Natl. Acad. Sci. USA 83, 7167-7171). Two modes of demethylation have been documented: site

specific demethylation that coincides in many instances with onset of gene expression of specific genes and a general genome wide demethylation that occurs during early development *in vivo* during cellular differentiation and in cancer cells (Feinberg, A.P. et al. (1983) Nature 301, 89-92; Razin, A. et al. (1986) Proc. Natl. Acad. Sci. USA 83, 2827-2831). The global demethylation is consistent with the hypothesis that a general demethylase activity which is activated at specific points in development or oncogenesis exists. It has been hypothesized that one mechanism regulating the pattern of methylation is the control of expression of methyltransferase (Szyf, M. (1991) Biochem. Cell Biol. 69, 764-767) and demethylase activities (Szyf, M. (1994) Trends Pharmacol. Sci. 7, 233-238). Although extensive information has been obtained on the enzymatic activity responsible for methylation and the regulation of its expression in the last two decades (Szyf, M. (1996) Pharmacol. Ther. 70, 1-37), the identity of the demethylase has remained a mystery. It is clear however that to fully understand how patterns of methylation are formed and maintained and to determine their role in development, physiology and oncogenesis, one has to identify the demethylase enzyme(s). Two main difficulties have inhibited the identification of this enzyme. First, it is believed that demethylation of a methylated cytosine is chemically highly unlikely since it involves breaking a very stable C-C bond. Second, demethylation occurs at very defined stages in development (Brandeis, M. et al. (1993) Bioassays 15, 709-713) and identifying an adequate tissue source for this enzyme is critical.

Whereas no *bona fide* demethylase has been identified to date, alternative biochemical mechanisms involving exchange of methylated cytosines with non-

5 methylated cytosines have been described. One previously proposed mechanism is removal of the methylated base by a glycosylase and its replacement with a non-methylated nucleotide utilizing an "excision-repair" mechanism (Razin, A. et al. (1986) Proc. Natl. Acad. Sci. USA 83, 2827-2831). Glycosylase activities that can remove methylated cytosines from DNA have been demonstrated by Vairapandi and Duker (Vairapandi, M. et al. (1993) Nucl. Acids Res. 21, 5323-5327) and more recently by Jost (Jost, J. P. et al. (1995) J. Biol. Chem. 270, 9734-9739). However it is not clear whether this activity is responsible for the general demethylation observed in cellular differentiation. The fact that the activity identified by Jost acts specifically on hemimethylated sequences (which is not the natural substrate in most cases) and can remove thymidines as well as 5-methylcytosines, supports a repair function for this glycosylase-demethylase (Jost, J. P. et al. (1995) J. Biol. Chem. 270, 9734-9739). An alternative mechanism involving a RNA dependent activity has been recently described by Weiss et al. (Weiss et al., 1996). This proteinase-insensitive RNA dependent activity has been shown to catalyze the excision and replacement of a methylated CpG dinucleotide with a nonmethylated CpG dinucleotide that is contained in a DNA-RNA hybrid molecule (Weiss, A. et al. (1996) Cell 87, 709-718). This activity which was identified in differentiating cells in culture was proposed to be involved in demethylation during development. These previous findings demonstrate that the common accepted model in the field has been that a *bona fide* demethylase does not exist.

It has been previously proposed that the extensive hypomethylation observed in cancer cells might be a consequence of activation of demethylase activity by



oncogenic pathways (Szyf, M.(1994) Trends Pharmacol. Sci. 7, 233-238; Szyf, M. et al. (1995) J. Biol. Chem. 270, 12690-12696). In accordance with this hypothesis we have shown that ectopic expression of v-Ha-ras had  
5 induced demethylation activity in the cells (Szyf, M. et al. (1995) J. Biol. Chem. 270, 12690-12696). Using an assay that directly measures the conversion of 3'<sup>32</sup>P labeled methyl dCMP (mdCMP) into dCMP, we have shown that nuclear extracts prepared from P19-Ras transfectants bear high levels of demethylase activity (Szyf,  
10 M. et al. (1995) J. Biol. Chem. 270, 12690-12696). Building on this observation, we hypothesized that cancer cell lines were a good source for demethylase. However, it is not evident that Ras expression in p19  
15 cells does reflect the situation in cancer cells. P19 is an embryonic cell and expression of Ras might be differentiating them.

It would be highly desirable to be provided with a *bona fide* DNA demethylase (DNA dMTase) to alter  
20 developmental programs for therapeutic and biological use.

#### SUMMARY OF THE INVENTION

In accordance with the present invention, we  
25 demonstrate the purification of a *bona fide* DNA demethylase (DNA dMTase) from a human lung cancer cell line A549, determine its kinetic parameters and substrate specificity. The DNA dMTase activity identified in this study converts methyl-dCMP (mdCMP) residing in the  
30 dinucleotide sequence mdCpG into dCMP whereas the methyl group is released as a volatile residue which was identified to be methanol. The activity is purified away from any trace amounts of dCTP, is insensitive to the DNA polymerase inhibitor ddCTP, is not  
35 affected by the presence of methyl dCTP (mdCTP) in the

reaction and does not exhibit exonuclease or glycosylase activities. The identification of this new enzyme points out to new directions in our understanding of how DNA methylation patterns are formed and  
5 altered.

One aim of the present invention is to provide a *bona fide* DNA demethylase (DNA dMTase).

In accordance with the present invention there is provided a DNA demethylase enzyme having about  
10 40 KDa, and wherein the DNA demethylase enzyme is over-expressed in cancer cells and not in normal cells.

In accordance with the present invention there is provided a cDNA encoding human demethylase which comprises a sequence set forth in SEQ ID NO:1.

15 In accordance with the present invention there is provided two mouse cDNAs homologous to the human cDNA, wherein the cDNA encoding mouse demethylase having a sequence set forth in SEQ ID NOS:5-7.

In accordance with the present invention there  
20 is provided a different human cDNA which encodes a protein homologous to the human demethylase having a sequence set forth in SEQ ID NO:3.

In accordance with the present invention there is provided the use of the expression of demethylase  
25 cDNAs to alter DNA methylation patterns of DNA *in vitro* in cells or *in vivo* in humans, animals and in plants.

The demethylase cDNAs expression may be under the direction of mammalian promoters, such as CMV.

The demethylase cDNAs expression may be under  
30 plant specific promoters to alter methylation in plants and to allow for altering states of development of plants and expression of foreign genes in plants.

The demethylase cDNAs expression may be in the antisense orientation to inhibit demethylase in cancer  
35 cells for therapeutic processes.

The expression of demethylase cDNA in mammalian cells may be to alter their differentiation state and to generate stem cells for therapeutics, cells for animal cloning and to improve expression of foreign genes.

5 In accordance with the present invention there is provided the use of the expression of demethylase cDNAs in bacterial or insect cells for production of large amounts of demethylase.

10 In accordance with the present invention there is provided the use of the expression of demethylase cDNAs for the production of protein in vertebrate, insect or bacterial or plant cells, such as antibodies against demethylase.

15 In accordance with the present invention there is provided the use of the sequence of demethylase cDNAs as a template to design antisense oligonucleotides and ribozymes.

20 In accordance with the present invention there is provided the use of the predicted peptide sequence of demethylase cDNAs to produce polyclonal or monoclonal antibodies against demethylase.

25 In accordance with the present invention there is provided the use of expression of cDNAs in two hybrid systems in yeast to identify proteins interacting with demethylase for diagnostic and therapeutic purposes.

30 In accordance with the present invention there is provided the use of expression of cDNAs in bacterial, vertebrate or insect cells to produce large amounts of demethylase for obtaining a x-ray crystal structure and for high throughput screening of demethylase inhibitors for therapeutics and biotechnology.

In accordance with the present invention there is provided a volatile assay for high throughput

screening of demethylase inhibitors as therapeutics and anticancer agents which comprises the steps of:

- a) using transcribed and translated demethylase cDNAs *in vitro* to convert methyl-cytosine present in methylated DNA samples to cytosine present in DNA and volatilize methyl group;
- b) determining the absence or minute amount of volatilize methyl group as an indication of an active demethylase inhibitor.

In accordance with the present invention there is provided a volatile assay for the diagnostics of cancer in a patient sample which comprises the steps of:

- a) determining demethylase activity in patient samples by assaying conversion of methyl-cytosine present in methylated DNA to cytosine present in DNA and its volatilization as methyl groups released as methanol;
- b) determining the presence or minute amount of volatilized methyl released as methanol groups as an indication of cancer in the patient sample.

In accordance with the present invention there is provided the use of an antagonist or inhibitor of DNA demethylase for the manufacture of a medicament for cancer treatment, for restoring an aberrant methylation pattern in a patient DNA, or for changing a methylation pattern in a patient DNA.

Such an antagonist is a double stranded oligonucleotide that inhibits demethylase at a  $K_i$  of 50nM, such as  $[C^mGC^mGC^mGC^mG] \cdot [G^mCG^mCG^mCG^mC]_n$

The inhibitors include, without limitation an anti-DNA demethylase antibody, an antisense of DNA demethylase or a small molecule such as any derivative of imidazole.

The change of the methylation pattern may activate a silent gene. Such an activation of a silent gene permits the correction of genetic defect such as found for  $\beta$ -thalassemia or sickle cell anemia.

5           The DNA demethylase of the present invention may be used to remove methyl groups on DNA *in vitro* such as needed for cloning DNA.

10           The DNA demethylase of the present invention or its cDNAs may be used, for changing the state of differentiation of a cell to allow gene therapy, stem cell selection or cell cloning.

          The DNA demethylase of the present invention or its cDNAs may be used, for inhibiting methylation in cancer cells using vector mediated gene therapy.

15           In accordance with the present invention there is provided an assay for the diagnostic of cancer in a patient, which comprises determining the level of expression of DNA demethylase by either RT-PCT, ELISA or volatilization assay of the present invention in a  
20           sample from the patient, wherein overexpression of the DNA demethylase is indicative of cancer cells.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

25           Figs. 1A to 1B illustrate the purification of demethylase (DNA dMTase) from human A549 cells;

          Figs. 2A and 2C illustrate that DNA dMTase is a protein inhibited by RNA and not by ddCTP, mdCTP;

          Figs. 2B and 2D illustrate the kinetics of DNA dMTase activity;

30           Figs. 3A to 3C illustrate the product of DNA dMTase activity is cytosine and it exhibits no exonuclease or glycosylase activity;

          Figs. 4A-4C illustrate the demethylation reaction releases methanol as a volatile residue;

Fig. 4D illustrates the transfer of a proton from water to regenerate cytosine;

Figs. 4E-4F illustrate that the volatile product is methanol;

5           Fig. 5 illustrates the suggested demethylation reaction;

Figs. 6A-6D illustrate the substrate Specificity of DNA dMTase;

10           Figs. 7A-7D illustrate chromatographic isolation of dMTase from human A549 cells;

Figs. 8A-8B illustrate the alignment between the MDB domain of MeCP2 and demethylase and the predicted amino acid sequence of human demethylase;

15           Fig. 8C illustrates the mRNA encoded by demethylase;

Figs. 9A-9F illustrate the cDNA and their predicted amino acid of demethylases and homologues of the present invention (SEQ ID NOS:1-8);

20           Figs. 10A-B illustrate a mammalian expression vector of dMTase and *in vitro* translated dMTase polypeptide;

Fig. 10C illustrates that *in vitro* translated DNA dMTase releases volatile methyl residues from methylated DNA;

25           Fig. 10D illustrates that *in vitro* translated DNA dMTase transform methylated cytosines to cytosines;

Fig. 11A illustrates that transiently transfected demethylase releases volatile residues from methylated DNA;

30           Fig. 11B illustrates the polypeptide expressed from transiently transfected demethylase;

Figs. 11C-11E illustrate that transiently transfected demethylase transforms methylated cytosines to cytosines in a protein dependent manner;

Fig. 11F illustrates that the transformation of methylated cytosine to cytosine by transiently transfected demethylase depends on the concentration of substrate;

5        Fig. 12A illustrates that transiently transfected demethylase catalyzes the transfer of a proton from tritiated water to regenerate cytosine;

Fig. 12B illustrates that the cloned demethylase releases methanol from methylated DNA;

10       Figs. 13A-13C illustrate that the cancer cells express demethylase activity whereas normal cells do not;

Fig. 13D illustrates that demethylase mRNA is highly express in cancer cells;

15       Fig. 14A illustrates demethylase bacterial retroviral and mammalian expression vector;

Fig. 14B illustrates inhibition of demethylase activity by a specific inhibitor;

20       Fig. 14C illustrates inhibition of tumorigenesis in vitro by an inhibition of demethylase;

Fig. 15 illustrates inhibition of tumorigenesis in cell culture by induced expression of demethylase antisense vector;

25       Fig. 16 illustrates the inhibition of demethylase by a small molecule inhibitor imidazole; and

Fig. 17 illustrates a model for the inhibition of cancer growth by an inhibition of demethylase.

#### DETAILED DESCRIPTION OF THE INVENTION

30       The pattern of methylation is fashioned during development by a sequence of methylation and demethylation events. The identity of the demethylase has remained a mystery and alternative biochemical activities have been shown to demethylate DNA but no activity  
35       that can truly remove methyl groups from DNA has been

shown to date. Utilizing human lung carcinoma cells as a source for demethylase activity we demonstrate that mammalian cells bear a *bona fide* DNA demethylase (DNA dMTase) activity. DNA dMTase transforms methyl-C to C by catalyzing replacement of the methyl group on the 5 position of C with a hydrogen derived from water. DNA dMTase demethylates both fully methylated and hemimethylated DNA, shows dinucleotide specificity and can demethylate mdCpdG sites in different sequence contexts. This enzyme is different from previously described demethylation activities: it is proteinase sensitive, activated by RNase and releases different products.


DNA dMTase is a novel enzyme showing a new and unexpected activity that has not been previously described in any organism. The finding of a *bona fide* demethylase, points out new directions in our understanding of the biological role of DNA methylation.

In spite of the fact that it was previously shown that Ras expression in p19 cells can induce demethylation activity. It was not clear whether this demethylation activity is indeed a *bona fide* demethylase. One would predict that demethylase is present in embryonal cells. It was surprising to see that demethylation activity is present in cancer cells. The finding of high levels of demethylase in A549 cells is indeed an unexpected discovery.

In accordance with the present invention, it is shown and demonstrated that demethylation occurs by removal of a methyl group from methylated cytosine in DNA, that a hydrogen from water replaces the methyl group at the 5' position, that the resulting methyl group reacts with the remaining hydroxyl from water to generate methanol which volatilizes (Fig. 4E-F). Thus,



*bona fide* demethylation of DNA involves the following reaction:



5           The cDNA cloned in accordance with the present invention is the demethylase since it can convert methyl-cytosines in DNA to cytosines and volatilize the methyl groups on DNA when transcribed and translated in vitro which are released as methanol. This is a novel  
10 cDNA encoding a biochemical activity that has been not described before.

In accordance with the present invention, there is shown a model for the inhibition of cancer growth by an inhibition of demethylase (Fig. 17).

15

## EXPERIMENTAL PROCEDURES

### Cell Culture

A549 Lung Carcinoma cells (ATCC: CCL 185) were grown in Dulbecco's modified Eagle's medium (with low  
20 glucose) supplemented with 10% fetal calf serum, 2 mM glutamine, 10 U/ml ciprofloxacin. Human Skin Fibroblasts #72-213A MRHF were obtained from BioWhittaker, Bethesda and were grown in Dulbecco's modified Eagle's medium supplement with 2% fetal calf serum, 2 mM glutamine.  
25 H446 Lung carcinoma cells (ATCC: HTB 171) was grown in RPMI 1640 medium with 5% fetal calf serum.

### Preparation of nuclear extract

Nuclear extracts were prepared from A549 cultures at near confluence as previously described (Szyf  
30 et al., 1991; Szyf et al., 1995). The cells were trypsinized, collected and washed with phosphate-buffered saline and suspended in buffer A (10 mM Tris, pH 8.0, 1.5 mM MgCl<sub>2</sub>, 5mM KCl, 0.5% NP-40) at the concentration of 10<sup>8</sup> cells per ml for 10 min. at 4°C. Nuclei were  
35 collected by centrifugation of the suspension at 1000 g

for 10 minutes. The nuclear pellet was resuspended in buffer A (400  $\mu$ l) and collected as described in the experimental procedures. A nuclear extract was prepared from the pelleted nuclei by suspending them in  
5 buffer B (20 mM Tris, pH 8.0, 25% glycerol, 0.2 mM EDTA and 0.4 mM NaCl) at the concentration of  $3.3 \times 10^8$  nuclei per ml and incubating the suspension for 15 min. at 4°C. The nuclear extract was separated from the nuclear pellet by centrifugation at 10,000g for 30 min-  
10 utes. Nuclear extract were stored in -80°C for at least two months without loss of activity.

#### Chromatography on DEAE-Sephadex

A freshly prepared nuclear extract (1 ml, 1.1 mg) was passed through a Microcon™ 100 spin column, the  
15 retainant was diluted to a conductivity equivalent to 0.2 M NaCl in buffer L and applied onto a DEAE-Sephadex column (Pharmacia) (1.0 x 5 cm) that was preequilibrated with buffer L (10 mM Tris-HCl, pH 7.5, 10 mM MgCl<sub>2</sub>) containing 0.2 M NaCl at a flow rate of 1  
20 ml/min. The column was then washed with 15 ml of the starting buffer (buffer L + 0.2 M NaCl) and proteins were eluted with 5 ml of a linear gradient of NaCl (0.2-5.0 M). 0.8 ml fractions were collected and assayed for demethylase activity after desalting  
25 through a Microcon™ 10 spin column (Amicon) and resuspension of the retainant in 0.8 ml buffer L. DNA demethylase eluted between 2-5.0 M NaCl.

#### Chromatography on S-Sepharose

Active DEAE-Sepharose column fractions were  
30 pooled, adjusted to 0.1 M NaCl by dilution and loaded onto an S-sepharose column (Pharmacia) (1.0 x 5 cm) which had been preequilibrated with buffer L containing 0.2 M NaCl at a flow rate of 1 ml/min. Following washing of the column as described in experimental proce-  
35 dures, the proteins were eluted with 5 ml of a linear

NaCl gradient (0.2-5.0M). 0.5 ml fractions were collected and assayed for DNA demethylase activity after desalting and concentrating to 0.2 ml using a Microcon™ 10 spin column. DNA demethylase activity eluted around 5.0 M NaCl.

#### Chromatography on Q-Sepharose

Active fractions from S-sepharose column were pooled, adjusted to 0.2 M NaCl by dilution and applied onto a Q-sepharose (Pharmacia) column (1.0 x5 cm) which had been equilibrated as described in the experimental procedures at a flow rate of 1 ml/min. The column was washed and the proteins were eluted with a linear NaCl gradient (0.2- 5.0 M). Fractions (0.5 ml) were collected, assayed for demethylase activity after desalting and concentrating to a final volume of 0.2 ml as described in the experimental procedures. The demethylase activity eluted around 4.8-5.0 M NaCl.

#### Gel-Exclusion Chromatography on DEAE-Sephacel

The pooled fractions of Q-sepharose column were adjusted to 0.2 M NaCl, loaded onto a 2.0 x 2.0 cm DEAE-Sephacel column (Pharmacia) and eluted with 10 ml of buffer L containing 0.2 M NaCl. The fractions (0.8 ml) were collected and assayed after concentration to about 180 µl with a Microcon™ 10 spin column for DNA demethylase activity. The activity was detected at fraction 4, which is very near the void volume (~200kDa).

#### Assay of DNA demethylase activity

To directly assay DNA demethylase activity in vitro two independent methods were applied.

(A) To assay the conversion of methyl-dCMP (mdCMP) to dCMP we used a previously described method (Szyf et al., 1995). Briefly,  $\alpha^{32}\text{P}$  labeled, fully methylated poly[mdC<sup>32</sup>PdG]n substrate was prepared as follows. One hundred ng of a double-stranded fully methylated

(mdCpdG) oligomer (Pharmacia) were denatured by boiling, which was followed by partial annealing at room temperature. The complementary strand was extended with Klenow fragment (Boehringer Mannheim) using methyl-5-dCTP (mdCTP, 0.1 mM) (Boehringer Mannheim) and [α-<sup>32</sup>P] GTP (100 μCi, 3000 Ci/mmol), and the unincorporated nucleotides were removed by chromatography through a NAP-5 column (Pharmacia). The NAP-5 chromatography was repeated to exclude minor contamination with unincorporated nucleotides. As a control a non-methylated poly[dC<sup>32</sup>pdG]n substrate was similarly prepared except that a nonmethylated dCpdG oligomer served as a template and dCTP was used in the extension reaction. The column fractions (30 μl), described in the experimental procedures were incubated with 1 ng of poly[mdC<sup>32</sup>pdG]n substrate for 1 hour at 37°C in a buffer L containing 25% glycerol (v/v) and 5 mM EDTA. The reacted DNA as well as a nonmethylated poly[dC<sup>32</sup>pdG]n and methylated [mdC<sup>32</sup>pdG]n nonreacted controls were purified by phenol/chloroform extraction and subjected to micrococcal nuclease digestion (100 μg at 10 μl) and calf spleen phosphodiesterase (2μg) (Boehringer) (Pharmacia) to 3' mononucleotides for 15 hours at 37°C. The digestion products were loaded onto a thin layer chromatography plate (TLC) (Kodak, 13255 Cellulose), separated in a medium containing, 132 ml Isobutyric acid:40 ml water: 4 ml ammonia solution, autoradiographed and the intensity of the different spots was determined using a phosphorimager (Fuji, BAS 2000). <sup>32</sup>P labeled substrates and tritium labeled substrates were phosphoimaged using BAS 2000 plate and BAS-TR2040 phosphorimager plate respectively.

(B) The second method determined removal of methylated residues from methylated DNA by measuring disappearance of <sup>3</sup>H-CH<sub>3</sub> or <sup>14</sup>C-CH<sub>3</sub> from the reaction mixture. 100 ng

of poly [dCdG]n double stranded DNA was methylated using SssI methylase (New England Biolabs) and an excess of [<sup>3</sup>H-methyl AdoMet (80 Ci/mmol; New England Nuclear)]. The tritiated methyl group containing DNA was purified from labeled AdoMet using NAP-5 column chromatography. All column purified fractions of DNA demethylase were assayed using the tritiated substrate. In a typical assay, 1 ng of DNA was incubated (at a specific activity of 4 x10<sup>6</sup>dpm/mg) with 30 µl of column fraction for one hour at 37°C in buffer L. To determine the number of methyl groups remaining in the DNA following incubation with the different fractions, 250 µl of water were added and the mixture was incubated at 65°C for 5 minutes. One hundred µl of the reaction mixture were withdrawn for liquid scintillation counting. Controls received similar treatment except that in place of a column fraction, an equal volume of buffer L was added. The number of methyl groups that were removed from the DNA by the different fractions was determined by subtracting the remaining counts in each of the fractions from the counts remaining in the control. All tests were carried out in triplicates. The results are presented as picomole methyl group removed. One unit of DNA dMTase activity is defined as: amount of enzyme that releases one picomole of methyl group from methylated dCpdG substrate in one hour at 37°C.

#### **Methyl removal assay using double-labeled substrates**

To determine whether the methyl group leaves the DNA and not any non-specific removal of tritium, we prepared SK plasmid DNA containing a tritiated hydrogen at the 6' position of cytosine and thymidine by growing the plasmid harboring bacteria in the presence of deoxy [6-<sup>3</sup>H] Uridine (22 Ci/mmol; Amersham) (10µCi/ml). The [6-<sup>3</sup>H]-cytosine containing pBluescript SK(+) was puri-

fied according to standard protocols and was methylated using an excess of [ $^{14}\text{C}$ -methyl] AdoMet (59 mCi/mmol; Amersham) (10  $\mu\text{Ci}$  per 100  $\mu\text{l}$  reaction) and SssI methylase. The double labeled DNA substrate was purified  
5 twice on a NAP-5 column. 15  $\mu\text{l}$  of DNA dMTase were incubated with 1 ng of double labeled DNA (specific activity of 2000 dpm/ng) for 1 hour at 37°C. Following incubation, the remaining  $^{14}\text{C}$  versus  $^3\text{H}$  counts were determined as described in the experimental procedures  
10 by scintillation counting (Wallac). The  $^{14}\text{C}$  counts were normalized against  $^3\text{H}$  counts. The controls received similar treatment except that instead of DNA dMTase, an equal amount of distilled water was added to them.

To determine the number of  $^3\text{H}$ -CH<sub>3</sub> in the gaseous  
15 phase, 1 ng of  $^3\text{H}$ -CH<sub>3</sub> poly [dCpdG] DNA were incubated with DNA dMTase overnight in a sealed tube (Pierce, Illinois, USA). 0.8 ml of air were removed from the tube using a gas tight syringe (Hamilton, Reno, Nevada) and injected into a sealed gas tight scintillation vial  
20 containing 10 ml OptiPhase scintillation fluid (Wallac, UK) and counted. As a control the DNA was incubated with an equal volume of buffer L and treated similarly.

#### **Synthesis of other methylated dC dinucleotides**

Poly [mdC<sup>32</sup>pdA] and [mdC<sup>32</sup>pdT] substrates were  
25 prepared as follows. About 0.5  $\mu\text{g}$  of 20 mer oligonucleotides 5'(GG)103', 5'(GT)103' and 5'(GA)103' were boiled and annealed at room temperature with oligonucleotide 5'CCCCC3', 5'CACACA3' and 5'CTCTCT3' respectively. The complementary strand was extended with  
30 Klenow fragment using m5dCTP (Boehringer Mannheim) and either [ $\alpha^{32}\text{P}$ ] dATP (100 $\mu\text{Ci}$ , 3000Ci/mmol) or [ $\alpha^{32}\text{P}$ ] dTTP (100  $\mu\text{Ci}$ , 3000 Ci/mmol) respectively. The unincorporated nucleotides were removed by chromatography through a NAP-5 column. Hemimethylated mdCpG substrate  
35 was prepared in a similar manner except that a nonmeth-

ylated poly dCpdG substrate (Boehringer) was used as template and m5dCTP and [ $\alpha^{32}\text{P}$ ]dGTP were used for extension as described in the experimental procedures.

#### Assay for nuclease and glycosylase activity

5            [ $^{32}\text{pmdCpdG}$ ]n substrate which included a labeled  $^{32}\text{P}$  5' to mdC was prepared as follows. About 100 ng of poly dCpdG DNA were boiled and partially annealed at room temperature. [ $\alpha^{32}\text{P}$ ]dCTP and cold dGTP were used for complementary strand extension as described in the  
10 experimental procedures. The free nucleotides were separated using NAP-5 column chromatography. The purified [ $^{32}\text{pmdCpdG}$ ]n DNA was subjected to methylation by SssI methylase using 320  $\mu\text{M}$  AdoMet. The DNA was repurified twice using a NAP-5 column. The methylated DNA (1  
15 ng) was incubated with either 30  $\mu\text{l}$  DNA dMTase, nuclear extract or buffer L. To determine whether  $\alpha^{32}\text{P}$  labeled residue is excised from the DNA it was directly applied (3 $\mu\text{l}$ ) onto a TLC plate. To determine whether the DNA was demethylated it was subjected to digestion with  
20 snake venom phosphodiesterase (0.2 mg in a 10 $\mu\text{l}$  reaction volume) (Boehringer Mannheim) which attacks the 3'-OH group releasing 5'-mononucleotides. The resulting mononucleotides were separated on TLC plates and autoradiographed.

25            To test whether dCTP copurifies with DNA dMTase, which may be involved in activities other than *bona fide* demethylation, 20  $\mu\text{M}$  of dCTP with 1  $\mu\text{l}$  of  $\alpha^{32}\text{P}$  labeled dCTP (3000 Ci/mmol) was loaded onto the column with nuclear extract. The  $^{32}\text{P}$  counts were measured in  
30 the flow through, washes and in the different fractions. About 1.1 million counts were loaded onto the DEAE-Sepharose column and were all recovered up to fraction 8.

            To determine whether DNA dMTase contains a DNA  
35 polymerase activity, DNA demethylase reactions were

performed in presence of 500  $\mu$ M of ddCTP (Pharmacia) or 500  $\mu$ M of m5dCTP (Boehringer Mannheim) at initial rate conditions.

To determine whether DNA dMTase is sensitive to  
5 RNase or Proteinase K treatment, DNA dMTase was pre-treated for 1 h at 56°C with 200  $\mu$ g/ml proteinase K (Sigma). A demethylation reaction was carried out with this pretreated fraction in the usual manner using both  
10 demethylation assays described in the experimental procedures. To test the effect of RNA digestion on the demethylation reaction, the fractions from different columns were treated with 100  $\mu$ g/ml RNase A (Sigma).

#### **Demethylation of pBluescript SK(+) Plasmid**

About 4  $\mu$ g plasmid pBluescript SK (Stratagene)  
15 was subjected to methylation using SssI methylase. The methylated plasmid (4 ng) was incubated with 30  $\mu$ l of DNA dMTase Fraction 4 of DEAE-Sephacel column under standard conditions, extracted with phenol: chloroform and precipitated with ethanol. About 1 ng of the plas-  
20 mid were subjected to digestion with 10 units each of either of the restriction endonucleases EcoRII (GIBCO-BRL), DpnI, HhaI or HpaII (New England Biolabs) before and after methylation as well as after DNA dMTase treatment in a reaction volume of 10  $\mu$ l for 2 hour at  
25 37°C. Following restriction digestion the plasmids were extracted with phenol:chloroform, ethanol precipitated and resuspended in 10  $\mu$ l. The plasmids were electrophoresed on a 0.8% (w/w) Agarose gel, transferred onto a Hybond Nylon membrane and hybridized with  
30 pBluescript SK(+) plasmid which was  $^{32}$ P labeled by random-priming (Boehringer Mannheim).

#### **Effect of Redox Reagents (NAD, NADH, NADP, NADPH and FeCl<sub>3</sub>) on demethylase activity**

The reagents were prepared at 100  $\mu$ M concentra-  
35 tion and added at a final concentration of 10  $\mu$ M to a standard methyl removal assay under initial rate condi-



tions as described in the experimental procedures. The methyl removal activity in presence of each of the cofactors was compared to a control DNA dMTase reaction.

5 **Determination of kinetic parameters**

For determination of kinetic parameters, the demethylation reactions were performed using both assays (generation of dCMP and removal of methyl) as described in the experimental procedures except that  
10 varying DNA concentrations from 0.1 nM to 2.5 nM were used in a total volume of 50  $\mu$ l including 30  $\mu$ l of DNA dMTase. Since it has been established by previous experiments that the reaction proceeds for at least 3 hours, the initial velocity of reaction was measured  
15 at one hour intervals. The velocity data was collected at each substrate DNA concentration range stated for both assays. The  $K_m$  and  $V_{max}$  values for DNA demethylase activity were determined from double reciprocal plots of velocity versus substrate concentration.

20 **Measurements of methanol production catalyzed by demethylase by gas chromatography**

Gas chromatography was performed with a Varian<sup>TM</sup> model 3400 GC equipped with a 30m Stabilwax<sup>TM</sup> column (0.053 cm i.d.: Restek Corporation). Nitrogen<sup>TM</sup> was  
25 used as carrier gas at a flow rate of 32 ml/min, the injector and detector chambers were at 200 and 300°C respectively. The column was maintained at 40°C for 5 minutes after sample injection.

The demethylase reaction was performed in eppendorf tubes kept within sealed scintillation vials with  
30 300  $\mu$ l of water as aqueous phase (in radioactive trapping experiments this was replaced by 300  $\mu$ l of methanol). The demethylase reaction was initiated in buffer L (10 mM  $MgCl_2$ , 10 mM Tris-HCl pH 8.0) with 500 ng of  
35 tritiated SK plasmid (6000 dpm/ $\mu$ l) and 100  $\mu$ l of demethylase at 37°C. After overnight incubation at 37°C,

the aqueous phase surrounding the eppendorf tube was transferred to a fresh eppendorf tube, 2  $\mu$ l of this mixture was injected in the gas chromatography using a gas tight syringe (Hamilton, Reno, Nevada).

5 **Coupled in vitro transcription translation**

The mRNAs encoded by the pcDNA 3.1/His Xpress demethylase constructs described above were transcribed and translated by coupled transcription-translation using Promega™ TNT reticulocyte lysate kit (according  
10 to manufacturer's protocol), 2  $\mu$ g of each construct and 40  $\mu$ Ci of [<sup>35</sup>-S]methionine (1,000Ci/mmol, Amersham) in a 50  $\mu$ l reaction volume. To purify non labeled in vitro translated demethylase, coupled in vitro transcription and translation was performed as above but in the pres-  
15 ence of cold methionine. The translation products were bound to a Probond™ nickel column (Invitrogen) and demethylase was eluted according to the manufacturer's protocol with increasing concentrations of imidazole. Demethylase is eluted at 350-500mM imidazole. The imi-  
20 dazole eluted demethylase was dialyzed and concentrated by lyophilization.

**Gas chromatography coupled with Mass spectrometry (GC-MS) Analyses for identification of volatile product of**  
25 **demethylase catalyzed reaction as methanol**

The demethylation reactions (volume 50 l) were run in conical vials having a total internal volume of 350 microlitres. The vials were closed with a teflon-lined screw cap and left at room temperature for 18 h.  
30 The vials were cooled in an ice bath, opened and 10 mg of NaCl and 50 microlitres of toluene were added. The vials were frequently shaken over a period of 1 h. The toluene phases were pipetted into clean vials in a manner to rigorously exclude water carry over. Anhydrous  
35 sodium sulfate (5 mg) was added to the toluene extracts to remove water, and the toluene phases were pipetted

into autoinjector vials for GC/MS analysis. Aliquots of 3 microlitres were analyzed under the following instrumental conditions: Instrument: Hewlett-Packard 5988A; Column: 30 m x 0.25 mm i.d. fused quartz capillary with 0.25 micron DB-1 liquid phase, programmed after an initial hold for 1 min at 70 deg at 5 deg/min to 80 deg, then ramped ballistically to 280 deg for bake-out for 5 min; Injector and interface temperatures: 250 deg; Helium flow rate 1.5 ml/min; Mass spectrometer: ion source 200 deg, 70 eV electron impact ionization, scanning from m/z 10 to 50 in full scan mode was begun 6 s after injection, and ceased at 1.5 min to avoid acquisition of the intense toluene solvent peak.

**Human A549 cells bear a demethylase activity that could be purified away from dCTP and DNA MeTase**

The use of an appropriate cellular source and a direct assay for demethylase activity are obviously critical. As we have previously shown that demethylase activity was induced in response to ectopic expression of the Ras oncogene (Szyf et al., 1995) we reasoned that cancer cells might bear high levels of demethylase activity. Based on preliminary studies demonstrating the presence of high levels of demethylase activity in the human lung carcinoma cell line A549, we have chosen this cell line for our further studies and purification steps. Previous studies have used indirect measures such as increased sensitivity to methylation-sensitive restriction enzymes as indicators of demethylase activity (Weiss et al., 1996; Jost et al., 1995). To directly measure the conversion of 5-mdCMP in DNA to dCMP, we have utilized a completely methylated <sup>32</sup>P labeled [mdC<sup>32</sup>pdG]n double stranded oligomer which we had previously described (Szyf et al., 1995). Following incubation with the different fractions, the

DNA is purified and subjected to cleavage with micrococcal nuclease to 3' mononucleotides. The 3' labeled mdCMP and dCMP are separated by thin layer chromatography (TLC) and the conversion of mdCMP to dCMP is directly determined. This assay provides a stringent test for *bona fide* demethylation and discriminates it from previously described 5mCpC replacement activities (Jost et al., 1995; Weiss et al., 1996). The glycosylase-demethylase activity described by Jost et al. (Jost et al., 1995) will require the presence of a ligase activity and an energy source for replacement of mdC with C to be detected by our assay, whereas the demethylase activity described by Weiss et al. will not be detected since it replaces the intact mdC<sup>32</sup>pdG dinucleotide with a cold dCpdG without altering its state of methylation (Weiss et al., 1996).

Nuclear extracts were prepared from A549 cells, applied onto a DEAE-Sephadex column, eluted with a linear gradient from 0.2-5.0M NaCl and the fractions were assayed for demethylase (dMTase) activity as described in the experimental procedures. As shown in Fig. 1(A) a clear peak of dMTase activity is eluted at the high salt fraction 10.

Conversion of methylated cytosine to cytosine:  
Nuclear extracts prepared from A549 cells (1.1 mg) were passed through an AMICON™ 100 spin column. The retainant (98.56 mg, 0.2 mg/ml) was loaded onto a DEAE-Sephacrose column, the different chromatographic column fractions eluted by a linear NaCl gradient (0.2-5M) were desalted and (30 µl) incubated with 1 ng of [mdC<sup>32</sup>pdG]n double stranded oligomer for 1 hour at 37°C, digested to 3' mononucleotides and analyzed on TLC as described in the experimental procedures. Control methylated (ME) and nonmethylated (NM) [dC<sup>32</sup>pdG]n substrates were digested to 3' mononucleotides and loaded on the TLC

plate to indicate the expected position of dCMP and mdCMP. The active fraction is indicated by an arrow. This fraction was loaded on S-Sepharose followed by Q-Sepharose and DEAE-Sepharose fractionation.

5           The first chromatography step purified the dMTase activity from the bulk of nuclear protein (Fig. 1B) and is a very effective purification step.

10           DNA dMTase activity as measured by the release of volatile methyl residues. The different column fractions were incubated with 1ng ( $4 \times 10^6$  dpm/ $\mu$ g) of [ $^3$ H]-CH<sub>3</sub>-[mdCpdG]<sub>n</sub> oligomer and the release of volatile methyl residues was determined (-) and presented as total dpm). The results are an average of three independent determinations. Protein concentration was  
15           determined using the Bio-Rad Bradford kit (-). The elution profile of 20  $\mu$ M of [ $^{32}$ P]- $\alpha$ -dCTP incubated with the protein was determined by scintillation counting of the different DEAE fractions (-) and presented as fraction of dCTP loaded on the column.

20           To exclude the possibility that the DNA dMTase activity detected in our assay is carried by the DNA MeTase, we assayed the fractions for DNA MeTase activity using a hemimethylated DNA substrate as previously described (Szyf et al., 1991). As observed in Figure  
25           1B DNA MeTase activity is detected in the second and third fractions, thus our fractionation separated DNA dMTase away from the DNA MeTase suggesting that they are independent proteins.

30           There is a remote possibility that the demethylation observed is not a *bona fide* demethylation but a consequence of a glycosylase removal of mC, followed by removal of the remaining deoxyribose-phosphate by AP (apyrimidine) nuclease, repair of the gap catalyzed by DNA polymerase using trace dCTP contained in the frac-  
35           tion and ligation of the break with ligase in the pres-

ence of residual ATP. For this hypothesis to be consistent with our data, four independent enzymes and two cofactors have to cofractionate with DNA dMTase. To exclude the possibility that a trace amount of dCTP is bound to DNA dMTase active fraction, we have added 20  $\mu$ M of  $^{32}$ P labeled dCTP ( $10 \times 10^6$  cpm) to the nuclear extract and determined its elution profile on the DEAE column. Less than background cpm (10 cpm) were detected in the DNA dMTase active fraction suggesting that our first column purifies dCTP away from the DNA dMTase at least  $1 \times 10^6$  fold (Fig. 1B). If any dCTP is present in the nuclear extract, the remaining concentration after fractionation on DEAE is well below the Kms of the known DNA polymerases. The possibility that dCTP is so tightly bound to the enzyme that it could not be replaced by the exogenous  $^{32}$ P labeled dCTP is very remote since an enzyme using dCTP as substrate must readily exchange dCTP.

The active fraction 10 was further fractionated sequentially on the following columns: S-Sepharose and Q-Sepharose. The DNA dMTase eluted at the high salt fraction from both columns as determined by the [mC $^{32}$ pG]n demethylation assay (Fig. 1A). The ion exchange chromatography was followed by chromatography on DEAE-Sephacel.

The fact that we have maintained our activity even after 4 fractionation steps (Table 1) and that only a single polypeptide is apparent after the last purification step argues strongly against the possibility that the activity detected in our study is a repair or replacement activity. Any replacement mechanism must involve a number of proteins and additional cofactors and substrates. In summary, the chromatography of the demethylase activity in A459 cells provides strong

support to the hypothesis that mammalian cells bear a *bona fide* demethylase activity.

**DNA dMTase releases a volatile derivative**

A *bona fide* demethylation has to result in  
5 release of the methyl group as a volatile derivative  
such as CO<sub>2</sub>, methanol, methane or formaldehyde. We  
have therefore incubated a {[<sup>3</sup>H] -CH<sub>3</sub>-dCpdG}n double  
stranded oligonucleotide with the different column  
fractions and the rate of release of the tritiated  
10 methyl from the aqueous phase was determined by scin-  
tillation counting of the remaining radioactivity in  
the reaction mix. As demonstrated in Fig. 1b (dia-  
mond), the dMTase active fractions release labeled  
methyl groups from the methylated substrate.

15 **DNA dMTase is a protein which is inhibited by RNA, does  
not involve an exchange activity and does not require  
additional cofactors**

DNA dMTase activity measured either as transfor-  
20 mation of mdC to C (Fig. 2a) or as release of volatile  
methyl residues (Fig. 2c) is abolished after proteinase  
K treatment and is not inhibited but rather enhanced  
following RNase treatment. 500 μM of ddCTP which  
inhibits DNA polymerase does not inhibit demeth-  
25 ylation of the [mdC32pdG]n substrate, nor is it inhib-  
ited by high concentrations of methyl-dCTP (500 μM)  
(Fig. 2a), which is consistent with the hypothesis that  
demethylation does not involve an excision and replace-  
ment mechanism. If a replacement mechanism is involved  
30 in demethylation, the presence of mdCTP should result  
in incorporation of methylated cytosines and essential  
inhibition of demethylation. Thus, the DNA dMTase  
identified here is a protein and not an RNA and is une-  
quivocally different from the previously published RNA  
35 based or glycosylase based demethylase activities.

The DNA dMTase reaction proceeds without any requirement for additional substrates such as dCTP, redox factors such as NADH and NADPH or energy sources such as ATP (data not shown). As observed in Fig. 2b and 2d, the DNA dMTase reaction maintains its initial velocity up to 90 minutes and continues up to 120 minutes. This time course is inconsistent with dependence on enzyme-bound additional nonreplenishable substrates such as dCTP or ATP or a nonreplenishable redox factor such as NADH or NADPH. Exhausting the nonreplenishable substrate or redox factor would have resulted in rapid deceleration of the initial velocity.

**A product of the demethylation reaction is deoxyCytosine in DNA**

What is the product of the demethylation reaction? The results presented above (Fig. 1a, 2a and b) based on a one dimension TLC separation show that DNA dMTase generates dC from mdC in DNA. To further substantiate this conclusion, we subjected DNA dMTase treated DNA to remethylation with the CpG MeTase M.Sss I which can transfer a methyl group exclusively to dC. The results presented in Fig. 3a show that the demethylated product of DNA dMTase is dC since it is completely remethylated with M.Sss I. The identity of the demethylated product as dC was further established by a two-dimension TLC analysis demonstrating that the product of dMTase comigrates with a cold dCMP standard in both dimensions (Fig. 3b).

DNA dMTase does not release a nucleotide, a phosphorylated base or phosphate from methylated DNA when incubated with a [32pmdCpdG]n substrate which included a labeled 32P 5' to mdC or our standard methylated substrate (Fig. 1) where 32P is 3' to the m5dC (Fig. 3c). Nuclear extracts which obviously contain a number of glycosylases and nucleases release phospho-



rylated derivatives in the same assay (Fig. 3c). dMTase transforms the methyl cytosine in the [32pmdCpdG]<sub>n</sub> substrate to cytosine as demonstrated when the reacted DNA is digested to 5' mononucleotides (Fig. 3c +V PDS) and analyzed by TLC. Since this reaction does not involve release of a 32P derivative (Fig. 3c -V PDS), it demonstrates that dMTase transforms methylated cytosines to cytosines on DNA without disrupting the integrity of the DNA substrate by glycosylase or nuclease activity .

**The second product of the dMTase reaction is methanol**

What is the identity of the leaving group? The results presented in Fig1b suggest that the labeled methyl leaves the DNA as a volatile compound. The demethylase reaction involves release of the methyl group *per se* whereas the cytosine base ring remains in the aqueous phase. Fig. 4a demonstrates this point by using a methylated plasmid labeled with a <sup>3</sup>H-hydrogen at the sixth position of cytosine and [14C]-methyl at the fifth position of cytosine as a substrate.

The three most obvious candidates the methyl group is leaving as are formaldehyde, carbon dioxide, and methanol. Methadone trapping for labeled formaldehyde detection and sodium hydroxide trapping for labeled carbon dioxide detection were both negative in identifying the form in which the methyl group is leaving in the dMTase reaction (data not shown). The other possible chemical form that the methyl group may leave the DNA as, is methanol. Since methanol is a volatile compound, a simple method to measure generation of methanol is a scintillation-volatilization assay (see Fig. 4b for description). Volatilization assays have been previously used to measure release of methanol in demethylation reactions. The demethylation reaction mix containing the labeled {[<sup>3</sup>H] -CH<sub>3</sub>-dCpdG}<sub>n</sub> substrate

with either dMTase or no enzyme, as a control, is added to an uncapped 0.5 ml tube which is placed in a sealed scintillation vial containing scintillation fluid. Released methanol is volatile, diffuses out of the open reaction tube and is mixed with the excess of the scintillation fluid in the vial registering as counts in the scintillation counter. As a control indicating that methanol is volatilized under the conditions of our assay, we incubated approximately equal counts of radioactively labeled methanol under the same conditions and measured the counts in a scintillation counter at different time points. As observed in Fig. 4c the majority of methanol in the reaction tube volatilizes from the reaction tube into the scintillation fluid following an overnight incubation at 37°C. The experiment shown in Fig. 4b demonstrates that volatilized label is released from methylated DNA only in the presence of dMTase.

The identity of the volatile group has been determined to be methanol by a gas chromatography (GC) analysis. The demethylation and control reactions (indicated in Fig. 4e) were performed in an uncapped tube placed in a sealed scintillation vial containing a larger volume (300 $\mu$ l) of water. The volatile residue diffuses into the surrounding water and mixes with it. A 2  $\mu$ l sample of the surrounding water was injected into a GC column as described in the methods. As shown in Fig. 4e, the volatile compound released by dMTase in a dose response manner coelutes with methanol. Release of methanol is observed only in the presence of both dMTase and methylated DNA. No methanol is released when dMTase is reacted with nonmethylated DNA, demonstrating that methanol is a product of demethylation of DNA.

The leaving group was also identified as methanol using gas chromatography coupled with Mass spectrometry (GC-MS). As illustrated in Fig. 4f., incubation of methylated DNA with dMTase (dMTase+ME-DNA) results in release of a peak with the retention time and mass spectrum (peaks are identified at 32 and 29 atomic mass which are the atomic masses of methanol and ionized methanol respectively) which is consistent with its identification as methanol. Incubation of dMTase with nonmethylated DNA does not release methanol indicating that methanol is a product of the demethylation reaction. No methanol is released when the samples are incubated with dMTase treated with protease K indicating that the release of methanol from methylated DNA is catalyzed by an enzymatic activity.

**Demethylation involves transfer of a hydrogen from water to regenerate cytosine**

If demethylation involves removal of the methyl moiety from mdC, a hydrogen has to be transferred to the carbon at the 5' position to regenerate cytosine. Since no redox factors are involved, what is the source of the hydrogen? To test the hypothesis that the source of the hydrogen is water, we incubated either non labeled [mdCpdG]n or [dCpdG]n double stranded DNA with DNA dMTase for different time periods in the presence of tritiated water, following which the DNAs were digested to 3' dNMPs, separated on TLC with non-radioactive standards for each of the 5 possible dNMPs and exposed to a tritium sensitive phosphorimaging plate. As seen in Fig.4d, dMTase catalyzes the transfer of a tritiated hydrogen from water to dCMP in methylated DNA in a time dependent manner only when methylated DNA is used as a substrate. Based on the experiments described in Fig.3 and 4 we propose that dMTase catalyzes the exchange of the methyl group at

the 5' position of cytosine in DNA with hydrogen from water and the methyl group reacts with the remaining hydroxyl group to form methanol (Fig. 5).

#### 5 Substrate and sequence specificity of DNA dMTase

Methylation of CpG dinucleotides is the most characterized modification occurring in genomic DNA<sup>8,48</sup>. The results presented in Fig.6 demonstrate that DNA dMTase is a general DNA dMTase activity that demethylates fully or hemimethylated dCpdG in DNA flanked by a variety of sequences which are distributed at different frequencies, but does not demethylate methylated adenines or methylated cytosines that do not reside in the dinucleotide CG. First, as shown in Fig.6a, a plasmid DNA methylated *in vitro* at all dCpdG sites with *M.Sss* I and all dCdCdGdG sites with *M. Msp* I (which methylates the external C in the sequence \*CCGG, thus enabling the determination of demethylation at the CC dinucleotide) and *in vivo* with the *E. coli* DCM MeTase at dCmdCdA/dTdGdG sites and with the DAM MeTase at dGmdAdTdC sites (adenine methylated) was treated with dMTase and the state of methylation of the plasmid was determined using the indicated methylation sensitive restriction enzymes. dMTase demethylates C\*G methylated sites as indicated by the sensitivity of the dMTase treated plasmid to *Hpa* II and *Hha* I but does not demethylate C\*C, C\*A or C\*T methylated sites as indicated by the resistance to *Msp* I and *Eco* RII restriction enzymes, or adenine methylation as indicated by its sensitivity to *Dpn* I. Second, bisulfite mapping analysis of methylation of 5 methylated C\*G sites residing in a *M.Sss* I *in vitro* methylated pMetCAT plasmid following dMTase treatment shows that all C\*G sites are demethylated irrespective of their flanking sequences thus excluding the possibility that demethylation is limited to CCGG or CGCG sequences (Fig. 6b).

Third, dMTase does not demethylate two fully methylated cytosine bearing oligomers [dmC32pdA]<sub>n</sub>, [mdC32pdT]<sub>n</sub> demonstrating that mdCpdA and mdCpdT are not demethylated by DNA dMTase (Fig. 6d). Fourth, dMTase demethylates a hemimethylated synthetic substrate [dCpdG]<sub>n</sub>\*[mdC32pdG]<sub>n</sub> (Fig. 6d). Demethylation of SK is complete under these conditions (Fig. 6a) whereas demethylation of a methylated [mdCpdG]<sub>n</sub> substrate is not complete under the same conditions (Fig. 6d). This can reflect differences in the sequence composition of the substrate and the frequency of methylated cytosines. The [mdCpdG]<sub>n</sub> contains on average 16 fold more methylated cytosines per molecule than plasmid DNA. Alternatively, these differences might reflect discrepancies in the assays used, restriction enzyme digestion versus a nearest neighbor analysis. To address this discrepancy we have labeled a fully methylated SK plasmid with [ $\alpha^{32}$ P]dCTP, 5-methyl-dCTP and the other dNTPs, subjected it to dMTase treatment and digested it to mononucleotides at different time points following the initiation of the reaction and subjected the samples to a TLC analysis. As shown in Fig. 6c, the SK plasmid is fully demethylated at 3 hours which is consistent with the results obtained with methylation sensitive restriction enzymes (Fig. 6a).

The  $K_m$  of DNA dMTase for hemimethylated and fully methylated DNA was determined by measuring the initial velocity of the reaction at different concentrations of substrate (Table 2). The calculated  $K_m$  for hemimethylated DNA is 6 nM which is two fold higher than the  $K_m$  for DNA methylated on both strands, 2.5-3 nM (Table 2). It is unclear yet whether this small difference in affinity to the substrate has any significance in a cellular context. Thus similar to the DNA MeTase DNA dMTase shows dinucleotide sequence

selectivity but in difference from DNA MeTase which shows preference to hemimethylated substrates dMTase prefers fully methylated DNA which is consistent with a role for DNA dMTase in altering established methylation patterns.

**Table 1****Purification of DNA dMTase**

Purification step	Total protein (µg)	Total dpm	pMole/µg	pMole/µg/h	Fold Purification
Nuclear extract	6000	1107.2	$5.5 \times 10^{-5}$	$1.833 \times 10^{-5}$	-
DEAE-Sephadex	3.75	5844	0.4674	0.156	8445.5
SP-Sepharose	0.77	5106	1.989	0.663	35939.84
Q-Sepharose	0.46	5335	3.4	1.13	62860.65
DEAE-Sepharcel	0.018	1834	30.57	10.19	552243.2

10

**Table 2****Kinetic parameters for DNA dMTase**

Method	$K_m$ (DNA)	$V_{max}$ (pMole/h)
Methylated oligo CpG	2.5 nM	340
Hemi-methylated CpG	6.0 nM	402
Methylated SK-DNA	3.3 nM	40.42

**Cloning and construction of demethylase expression vectors****15 PCR amplification of the MBD domain of the putative demethylase candidate cDNA**

One µg of total RNA prepared from the human small lung carcinoma cell line A549 was reverse transcribed using Superscript reverse transcriptase and random primers (Boehringer) in a 25 µl reaction volume according to conditions recommended by the manufacturer (GIBCO-BRL). Five µl of reverse transcribed cDNA were subjected to an amplification reaction with Taq polymerase (Promega, 1 unit) using the following set of

primers: sense 5'CTGGCAAGAGCGATGTC 3' SEQ ID NO:9,  
antisense 5'AGTCTGGTTTACCCTTATTTTG 3' SEQ ID NO:10.

Amplification conditions were: step 1. 95°C 1 min.; step 2: 94°C 0.5 min; step 3: 45°C 0.5 min.; step  
5 4: 72°C 1.5 min; steps 2-4 were repeated 30 times. MgCl<sub>2</sub> was adjusted to 1 mM according to conditions recommended by the manufacturer. The PCR products were cloned in pCR2.1 vector (Invitrogen) and the sequence of the cDNAs was verified by dideoxy-chain termination  
10 method using a T7 DNA sequencing kit (Pharmacia). The amplified fragment was excised from the plasmid with EcoRI, labeled with a Boehringer random prime labeling kit according to manufacturer's protocol and alpha <sup>32</sup>P-dCTP. The labeled probe was used to screen a HeLa cell  
15 cDNA library in λTriplEx phage (Clontech) according to standard procedures. Positive clones were identified and further purified by serial dilutions for 4 rounds. The insert in the pTriplEx plasmid was excised from the phage according to manufacturer's protocols and the  
20 identity of the insert was verified by sequencing. The insert was excised by NotI restriction and subcloned into either the inducible expression vector: Retro tet on (Clontech) in the sense and antisense orientation or the pcDNA3.1/His Xpress vector in all three frames and  
25 in the antisense orientation.

#### **Transfection and expression of demethylase in vertebrate cells**

Ten µg of either Retro tet on demethylase or  
30 pcDNA 3.1/His Xpress demethylase are mixed with 8 µl of transfection lypophilic reagent Pfx-2 (Invitrogen) and placed upon 100,000 mouse (3T3 Balb/c, human (A549) or monkey cells (CV-1) according to manufacturer's protocol in OPTIMEM medium for 4 hours. Cells are harvested  
35 after 48 hours and demethylation and demethylase activity is determined by measuring total genomic DNA meth-

ylation using standard techniques or a cotransfected *in vitro* methylated plasmid using a HpaII /MspI restriction enzyme analysis. Cellular transformation is measured by a soft agar assay.

5

#### **Demethylation of pBluescript SK(+) Plasmid**

About 4  $\mu$ g plasmid pBluescript SK (Stratagene) was subjected to methylation using SssI methylase. The methylated plasmid (4 ng) was incubated for different  
10 time points as indicated with 30  $\mu$ l of DNA dMTase Fraction 4 of DEAE-Sephacel<sup>TM</sup> column under standard conditions, extracted with phenol: chloroform and precipitated with ethanol. About 1 ng of the plasmid were  
15 subjected to digestion with 10 units each of either of the restriction endonuclease EcoRII (GIBCO-BRL), DpnI, or HpaII (New England Biolabs) before and after methylation as well as after DNA dMTase treatment in a reaction volume of 10  $\mu$ l for 2 hour at 37°C. Following  
20 restriction digestion the plasmids were extracted with phenol:chloroform, ethanol precipitated and resuspended in 10  $\mu$ l. The plasmids were electrophoresed on a 0.8% (w/w) Agarose gel, transferred onto a Hybond<sup>TM</sup> Nylon membrane and hybridized with pBluescript SK(+) plasmid which was <sup>32</sup>P labeled by random-priming (Boehringer  
25 Mannheim).

**dMTase activity coelutes with a ~45 KDa polypeptide when sized under denaturing conditions but migrates as a higher molecular weight complex under non denaturing  
30 conditions.** dMTase was purified up to 500,000 fold by four chromatographic steps (Table 1). We first determined the identity of the polypeptide associated with dMTase activity by SDS-PAGE analysis of the active  
fractions. As observed in Fig. 7a, a cluster of 4  
35 polypeptide bands from ~44 KDa to 35 KDa coelute with dMTase activity in the last two chromatographic steps



(the lower fragment might be a degradation product as evidenced by its abundance in the later chromatographic steps). However when the active DEAE-Sephacel fraction is size fractionated on a 4% non denaturing acrylamide column, the dMTase activity elutes at the high molecular weight of ~170 KDa (Fig. 7c, fraction 63). SDS-PAGE analysis of this fraction (63) reveals only two bands (Fig. 7b) observed in the active chromatographic fractions (Fig. 7a). To further determine whether dMTase is found in a multimeric complex, fraction 63 was size fractionated on a glycerol gradient (Fig. 7d) and DNA dMTase activity eluted at the ~170 kDa range. As only two main small polypeptides were identified in fraction 63 (approximately 35-43 KDa), dMTase is probably found in either a homomeric complex if only one of the two peptides is dMTase or a heteromeric complex if both polypeptides are associated with dMTase activity.

**a. Identification of a lead DNA dMTase candidate by homology search of dbEST**

As the purification of dMTase suggests that the dMTase is of very low abundance, only ~19 ng of dMTase could be isolated from 6 mg of nuclear extract (Table 1), we opted for cloning the dMTase based on its following functional properties. First, since dMTase specifically demethylates methylated CG dinucleotides, we assumed that it should bear the ability to recognize methylated CG dinucleotides. Second, the demethylase transforms methylated cytosine in DNA to cytosine. Third, the demethylase releases the methyl group as a volatile compound.

Previous reports have shown that proteins interacting with methylated DNA share a common domain (MDBD). A TBLASTN search of the dbEST database identified a novel expression tag cDNA (from a T-cell lymphoma Homo sapiens cDNA 5' end) (gb/AA361957/AA361957

EST71295) and the mouse homologue ((gb/W97165/W97165  
mf90g05.r1) from Soares mouse embryo NbME13.5) with  
unknown function that bears homology to the MDBD  
(Fig. 8a). A search of the GenBank database verified  
5 that it is a novel cDNA that has not been included in  
GenBank. Alignment of the novel EST and MeCP2 and  
MeCP1 associated protein has revealed no homology  
beyond the previously characterized MDBD which is con-  
sistent with a different function for this methylated  
10 DNA binding protein. A 201bp fragment bearing the  
sequence identified in the search was reverse tran-  
scribed and amplified from human lung cancer cell line  
A549 RNA and was used to screen a cDNA library from  
Hela cells. The largest insert cloned was of 1.36 kb  
15 size and its sequence identity with the EST sequence  
was determined. The cDNA is novel and has no homologue  
in GenBank and no function has ever been assigned to  
it. A virtual translation of the protein identified an  
open reading frame (ORF) of 262 amino acids (Fig. 8b).  
20 The ORF may extend further 5' as no in frame stop codon  
was found upstream of this ATG. However, RACE analy-  
ses and further searches of the dbEST have failed to  
identify 5' sequences upstream to the one identified in  
our screening.

25 A BLAST search of the candidate protein using  
the Predict protein server against a database of pro-  
tein domain families has identified only the MDBD  
domain and found no homologue to the sequence in the  
data base search. No other functional motifs were  
30 identified by the Prosite analysis. This is consistent  
with a novel biochemical function for this protein. A  
coiled coil prediction of the sequence identified a  
coiled coil domain which is known to play a role in  
protein protein interactions.

The identified cDNA encodes an mRNA that is widely expressed in human cells as revealed by a Northern blot analysis of human poly A+ mRNA (Fig. 8c) as one major transcript of ~ 1.6 kb which is close to the size of the cloned cDNA, verifying that the cloned cDNA does not represent a highly repetitive RNA but rather a mRNA encoded by a single or low copy number gene.

#### 10 In vitro translated candidate cDNA bears dMTase activity

A conclusive proof for the existence of a single protein that *bona fide* demethylates DNA is to demonstrate that an *in vitro* translated candidate cDNA can volatilize methyl groups from methylated DNA and transform a methyl cytosine to cytosine in an isolated system. The candidate dMTase cDNA was subcloned it into a pcDNA3.1/His Xpress (INVITROGEN) expression vector in the putative translation frame (pcDNA3.1His A) and in a single base frame shift (pcDNA3.1His B), and was *in vitro* transcribed and translated in the presence of <sup>35</sup>S-methionine and the resulting translation products were resolved by SDS-PAGE. Autoradiography revealed a ~40KDa protein (Fig. 10a). The apparent size of the *in vitro* translated protein is shorter by ~3-5 KDa from the apparent size of the purified protein. The cloned cDNA might be missing some upstream amino acids as discussed above or might be differently modified in human cells.

Two tests established whether the *in vitro* translated candidate cDNA is a *bona fide* dMTase. We first tested whether *in vitro* translated protein (purified on a Ni<sup>2+</sup> charged agarose resin) can volatilize and release methyl residues in [<sup>3</sup>H]-CH<sub>3</sub>-DNA using a radioactive trapping volatilization assay. To verify that the volatilized counts are true <sup>3</sup>H counts, a spectrum analysis was performed. As demonstrated in Fig.

10b no volatilization of tritiated methyl residues is observed in the misframe dMTase (misframe) whereas *in vitro* translated putative dMTase cDNA catalyzes the volatilization of  $^3\text{H}-\text{CH}_3$  residues which are trapped in the scintillation cocktail.

Second, *in vitro* translated dMTase cDNA transforms  $\text{CH}_3$ -cytosine residing in  $[^{32}\text{P}]-\alpha\text{-dGTP}$  labeled plasmid DNA or in [methyl-dC32pdG]<sub>n</sub> double stranded oligomer DNA to cytosine, whereas a frame shift in *in vitro* translated dMTase does not demethylate DNA (Fig. 10d). This demonstrates that the dMTase activity is dependent on the dMTase translation product and not a contaminating activity found in the *in vitro* translation kit that copurifies with the putative dMTase. The reaction carried out by the *in vitro* translated dMTase displays: dependence on the dose of *in vitro* translated product (Fig. 10c), time dependence (Fig. 10d) and dependence on translated protein (Fig. 10b & d misframe, Fig. 10c protease K treatment). Taken together, these results strongly suggest that the cDNA cloned here codes for a *bona fide* enzymatic DNA demethylase activity.

#### Transiently transfected dMTase cDNA demethylates DNA

dMTase cDNA and the pcDNA3.1HisC vector control were transiently transfected into human embryonal kidney cells to test whether the cDNA can direct expression of dMTase activity in human cells. The His-tagged proteins were bound to  $\text{Ni}^{2+}$  agarose resin and eluted from the resin with increasing concentrations of imidazole. The expression of the transfected dMTase was verified by a Western blot analysis (Fig. 11b). The imidazole fractions were assayed for their ability to volatilize and release methyl residues in  $[^3\text{H}]-\text{CH}_3\text{-DNA}$  using a radioactive trapping volatilization assay 1. As observed in Fig. 11a, imidazole fractions from

dMTase transfected cells volatilize [ $^3\text{H}$ ]- $\text{CH}_3$ , whereas no tritiated counts are detected in DNA treated with imidazole fractions from cells transfected with a misframe mutation of dMTase or non transfected cells. The transiently expressed dMTase transforms methylated cytosine in DNA to cytosine residing in two different substrates (Figs. 11c & 11d), in a protein dependent manner (Figs. 11c & 11e), and the reaction displays substrate dependence and saturability (Fig. 11f). Transiently expressed dMTase was loaded on a non denaturing glycerol gradient to determine its native MW. Similar to dMTase purified from human cells, cloned and purified dMTase activity fractionated at the 160-190 KDa range (data not shown). This is consistent with self association of cloned dMTase possibly mediated by the coiled-coil domain.

**Cloned DNA dMTase catalyzes a hydrolysis of 5-methylcytosine to release methanol**

We determined the mechanism by which methyl residues are released by the cloned dMTase (from Fig. 11) and compared it to the purified *bona fide* dMTase activity. Increasing amounts of non labeled [methyl-dCpdG] DNA were incubated with either the *bona fide* dMTase activity purified from A549 cells or the cloned dMTase in the presence of [ $^3\text{H}$ ] water for 3 hours followed by digestion to mononucleotides, a thin layer chromatography and autoradiography. As Fig. 12a shows, both reactions replace the methyl group in 5-methylcytosine with a proton donated from water as indicated by the presence of [ $^3\text{H}$ ] label in cytosine.

The identity of the leaving methyl group in the demethylation reaction catalyzed by the purified *bona fide* dMTase activity was shown to be methanol. In order to identify the form that the methyl residue leaves as in the demethylation reaction catalyzed by

the cloned dMTase an identical gas chromatography/mass spectrometry analysis of the reaction products was performed as in 1. Only the properly translated form of dMTase (both *in vitro* translated and transiently transfected and purified) is able to produce ions characteristic of methanol in a mass spectrometric analysis (mass of 32 and 29, Fig. 12b). These results suggest that the demethylation reaction catalyzed by the cloned dMTase is hydrolysis of the 5-methyl-cytosine to cytosine and methanol as described for the purified dMTase 1.

#### DNA dMTase activity is undetectable in nontransformed cells

The assays for dMTase activity described here and the cloning of DNA dMTase cDNA enables a study of its expression at different cellular states. Global hypomethylation of DNA is a common observation in cancer cells. This has been a perplexing observation, since DNA MeTase activity is elevated in cancer cells. Hyperactivation of DNA MeTase has been proposed to play a role in cancer development. This paradox raises questions on the proposed role of the elevated levels of DNA MeTase in cancer cells. One simple explanation that has been previously suggested to resolve this paradox is that cancer cells express induced levels of DNA dMTase. We compared the DNA dMTase activity in equal concentrations of DEAE-Sephadex fractionated nuclear extracts (fractions 9-10) prepared from a number of carcinoma cell lines H446, Colo 205, Hela, and A549 with a similar preparation from human skin fibroblast cells at initial rate conditions using [ $\text{methyl-}^3\text{H}$ ]dGp double stranded oligomer as a substrate. As observed in Fig. 13a, whereas DNA dMTase activity is readily observed in all carcinoma cell lines, it is undetectable in nontransformed human cells. The absence of dMTase activity in human primary cells

reflects the situation *in vivo* since dMTase activity is undetectable in preparations from different murine tissues whereas dMTase activity is present in a murine carcinoma cell line P19 that was transfected with the H-Ras protooncogene, or human tumors carried as xenografts in the same strain of mouse (Fig. 1a: COLO 205, A549. Hela). These conclusions were verified using the radioactive-trapping volatilization assay shown in Fig. 13c.

Since dMTase mRNA has been detected using a sensitive poly A+ Northern blot in all normal human tissues, we tested the hypothesis that the absence of detected dMTase activity in normal tissues reflects a quantitative difference in DNA dMTase mRNA between normal tissues and cancer lines. A Northern blot analysis and quantification of dMTase mRNA by a slot blot analysis shown in Fig. 13d using total RNA supports this hypothesis. Whereas minute levels of dMTase mRNA are detected in normal tissues, high levels of dMTase are expressed in a murine carcinoma cell line Y1 that bears a 30 fold amplification of *Ha-ras*.

**A second DNA demethylase dMTase2 identified in human and mouse**

cDNA sequences, predicted amino acid sequences, and GenBank accession numbers of both dMTase1 and dMTase2 from human and mouse are shown. We claim that the high level of identity of the two proteins (Figs 9c and e) suggests that the two proteins can perform the same function, DNA demethylation. The N-terminals of dMTase1 and dMTase2 contain a Methylated DNA Binding Domain (MBD) and near their C-terminals is a coiled-coil domain, however the middle portions of the protein sequences have no homology to any known structural or catalytic motif. Importantly, their middle regions are still extensively homologous suggesting that the cata-

lytic site of the demethylase activity lies in this area on both proteins.

**Induced expression of DNA demethylase in the Antisense orientation inhibits tumorigenesis ex vivo**

5           To test the hypothesis that inhibition of DNA dMTase can inhibit tumorigenesis tetracycline inducible vectors carrying the human dMTase1 cDNA in either the sense or antisense orientation were constructed and transiently transfected into HEK 293 cells, treated for 10 48 hours either in the presence or absence of doxycycline (a tetracycline analogue), selected for the last 24 hours with puromycin, and then plated on soft agar and allowed to grow for seven days. After seven days colonies were scored and the data presented clearly 15 show that doxycycline induced expression of the dMTase1 cDNA in the antisense orientation reduced colony formation (Fig. 15).

**Imidazole is a small molecule inhibitor of DNA demethylase activity**

20           A template small molecule, imidazole, was tested for the ability to inhibit DNA dMTase activity. In a volatilization of radioactive methyl residues assay, concentrations from 1 $\mu$ M to 10mM of imidazole were incubated in a typical volatilization of radioactive methyl 25 residues as described above. The graph clearly demonstrates a dose dependent inhibition of DNA dMTase activity by imidazole, and validates a rationale for testing imidazole based molecules as inhibitors of DNA dMTase activity (Fig. 16).

30 **Identification of DNA demethylase cDNAs and protein sequences**

**Fig. 9a** illustrates cDNA sequence of human dMTase1 (SEQ ID NO:1) and its predicted amino acid sequence (SEQ ID NO:2), including its Genbank location. **Fig. 9b** illustrates cDNA sequence of human dMTase2 (SEQ ID NO:3) and 35 its predicted amino acid sequence (SEQ ID NO:4), includ-



ing its GenBank location. **Fig. 9c** illustrates protein sequence alignment of human dMTase1 and human dMTase2. **Fig. 9d** illustrates cDNA sequence of mouse dMTase1 (SEQ ID NO:5) and its predicted amino acid sequence (SEQ ID NO:6), including its GenBank location. **Fig. 9e** illustrates cDNA sequence of mouse dMTase2 (SEQ ID NO:7) and its predicted amino acid sequence (SEQ ID NO:8), including its GenBank location. **Fig. 9f** illustrates protein sequence alignment of mouse dMTase1 and mouse dMTase2.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.

WHAT IS CLAIMED IS:

1. A DNA demethylase enzyme and/or homologue thereof having about 40 KDa, and wherein said DNA demethylase enzyme is overexpressed in cancer cells.
2. A cDNA encoding a human demethylase which comprises a sequence set forth in SEQ ID NOS:1 and 3.
3. A cDNA homologous to the cDNA of claim 2, wherein said cDNA encoding mouse demethylase set forth in SEQ ID NOS:5 and 7.
4. The use of the expression of demethylase cDNA of claims 2 or 3 to alter DNA methylation patterns of DNA *in vitro* in cells or *in vivo* in humans, animals and in plants.
5. The use of claim 4, wherein said demethylase cDNA expression is under the direction of mammalian promoters.
6. The use of claim 5, wherein said promoter is CMV.
7. The use of claim 4, wherein said demethylase cDNA expression is under plant specific promoters to alter methylation in plants and to allow for altering states of development of plants and expression of foreign genes in plants.
8. The use of claim 4, wherein said demethylase cDNA expression is in the antisense orientation to inhibit demethylase in cancer cells for therapeutic processes.

9. The use of claim 9, wherein expression of demethylase cDNA in mammalian cells is to alter their differentiation state and to generate stem cells for therapeutics, cells for animal cloning and to improve expression of foreign genes.

10. The use of the expression of demethylase cDNA of claims 2 or 3 in bacterial or insect cells for production of large amounts of demethylase.

11. The use of the expression of demethylase cDNA of claims 2 or 3 for the production of protein in vertebrate, insect or bacterial cells.

12. The use of claim 11 for producing antibodies against demethylase.

13. The use of the sequence of demethylase cDNA of claim 2 as a template to design antisense oligonucleotides and ribozymes.

14. The use of the predicted peptide sequence of demethylase cDNA of claim 2 to produce polyclonal or monoclonal antibodies against demethylase.

15. The use of expression of cDNA of claim 2 or 3 in two hybrid systems in yeast to identify proteins interacting with demethylase for diagnostic and therapeutic purposes.

16. The use of expression of cDNA of claim 2 or 3 in bacterial, vertebrate or insect cells to produce large amounts of demethylase for high throughput screening of

demethylase inhibitors for therapeutics and biotechnology and for obtaining the x-ray crystal structure.

17. A volatile assay for high throughput screening of demethylase inhibitors as therapeutics and anticancer agents which comprises the steps of:

- a) using transcribed and translated demethylase cDNA of claim 2 or 3 *in vitro* to convert methyl-cytosine present in methylated DNA samples to cytosine present in DNA and volatilize methyl group;
- b) determining the absence or minute amount of volatilize methyl group as an indication of an active demethylase inhibitor.


18. A volatile assay for the diagnostics of cancer in a patient sample which comprises the steps of:

- a) determining demethylase activity in patient samples by determining conversion of methyl-cytosine present in methylated DNA to cytosine present in DNA and volatilization of the methyl group released as methanol;
- b) determining the presence or minute amount of volatilized methyl group as an indication of cancer in said patient sample.

19. Use of an antagonist or inhibitor of DNA demethylase of claim 1 or 2 for the manufacture of a medication for cancer treatment, for restoring an aberrant methylation pattern in a patient DNA, or for changing a methylation pattern in a patient DNA.

20. Use according to claim 19, wherein said antagonist is a double stranded oligonucleotide that inhibits demethylase at a  $K_i$  of 50nM.

21. Use according to claim 20, wherein said oligonucleotide is



22. Use according to claim 19, wherein the inhibitor comprises an anti-DNA demethylase antibody or an antisense oligonucleotide of DNA demethylase or a small molecule.

23. Use according to one of claims 19 or 22, wherein the change of the methylation pattern activates a silent gene.

24. Use according to claim 23, wherein the activation of a silent gene permits the correction of genetic defect.

25. Use according to claim 24, wherein said genetic defect is  $\beta$ -thalassemia or sickle cell anemia.

26. Use of the demethylase of claim 1, for removing methyl groups on DNA *in vitro*.


27. Use of the demethylase of claim 1 or its cDNA of claim 2, for changing the state of differentiation of a cell to allow gene therapy, stem cell selection or cell cloning.

28. Use of the demethylase of claim 1 or its cDNA, of claim 2 for inhibiting methylation in cancer cells using vector mediated gene therapy.

29. An assay for the diagnostic of cancer in a patient, which comprises determining the level of expression of DNA demethylase of claim 1 in a sample

from said patient, wherein overexpression of said DNA demethylase is indicative of cancer cells.

1/50












FIGURE 1B




3/50









5/50




6/50











8/50



9/50


FIG. 4E

10/50

Fig - 4F




11/50




$$\Delta G_{\text{Reaction}} = (93) - (103 + 91.5) = (-101.5) \text{ Kcal}$$

FIG. 5


12/50




13/50



14/50



15/50



16/50




Fig - 7C

Fig - 7D

17/50

EST DCPALPPGKKEEVIRKSGLSAGKSDVYFSPGCKFRSKPQLARYLGNIVDLS  
 |||||  
 D P LP GW ++ RKSG SAGK DVY +P GK FRSK +L Y D S  
 |||||  
 MeCP2 15 DDPTLPEGWTRKIKQKSGRSAGKYDVYLINPQKAFRSKVELLIAYFEKVGDTIS 68


FEF - BA

MDCPALPPGW KKEEVIRKSG LSAGKSDVY FSPGCKFRS 40  
 ~~~~~  
 KPQLARYLGN TVDLSSFDNR TGKMMPSKLQ KMKQRLRNDP 80  
 ~~~~~  
 LNQNKGKPD LNTTLPIRQTA SIFKQPVTKV TNHPSNKKVKS 120  
 ~~~~~  
 DPQRMNEQPR QLFWEKRLQG LSASDVTEQI IKTMELPKGL 160  
 ~~~~~  
 QGVGPGSNDE TLLSAVASAL HTSSAPITGQ VSAAVEKNPA 200  
 ~~~~~  
 VWLNTSQPLC KAFIVTDEDI RKOEVERVOOV RKILEDALMA 240  
 ~~~~~  
 DILSRAADTE EMDIEMDSGD EA 262

homology to methylated DNA  
 binding domain  
 homology to coiled  
 coil domain

FEF - BB

18/50





## Human DNA demethylase cDNA-dMTase1 and predicted amino acid sequence

5' gggggcgtgg cccgagaag gcgagacaa gatggccgcc catagcgctt ggaggaccta  
 agaggcggtg gccggggcca cgcgccggc aggagggccg ctctgtcgc gccgctcta  
 tgatgcttgc gcgctccc gcgcgccgc cctgcgggcg ggcgggtct ccgggattcc  
 aaggctcgg ttacggaaga agcagcgc cggctggga ggggctgga tgcgcgcga  
 cccggggga gccgctgct gccggagca ggaggaggg gagagtgcg cggcggcag  
 cggcgtggc ggcactccg ccatagaca ggggggccag ggcagcgc tcgcccctc  
 cccggtgagc ggcgtgcga ggaaggcgc tcggggcggc gccgtggc gggggcgtg  
 gaagcaggc gccggggcg gcgctctg tggcgtggc cggggccgg gccgtggcg  
 gggacggga cggggccgg gccgggccg cggcgtccc ccgagtggc gcagcggcct  
 tggcggcgac ggcggcggc gcggcggcg cggcagcgg gccggcggc ccccccggc  
 ggagcggtc ccttcccgt cgggagcgc gggccgggg ccaggggac ccggggccac  
 ggagagcgg aagaggatg atggccggc cctcccccc ggatggaaga aggaggaagt  
 gatccgaaa tctgggctaa gtgctggcaa gagcgtgtc tactacttca gtccaagtgg  
 taagaagt c agaagcaag ctcagttggc aaggtaactg gaaatactg ttgatctcag  
 cagttttgac ttcagaactg gaaagatgat gcctagtaaa ttacagaaga acaacagag  
 actgcgaaac gatcctctca atcaaaataa gggtaacca gacttgaata caacattgcc  
 aattagacaa acagcatcaa ttttcaaca accggtacc aagtcacaa atcatcctag

19/50

FIG. 9A

20/50

taataaagtg aaatcagacc caaacgaat gaatgaacag ccacgtcagc ttttctggga  
 gaaaggaagga gaaaggaagga gaaaggaagga gaaaggaagga gaaaggaagga  
 actacccaaa ggtttcgaag gagttggtcc aggtagcaat gatgagaccc ttttatctgc  
 tgttgccagt gctttgcaca caagctctgc gccaatcaca gggcaagtct ccgctgctgt  
 ggaaaagaac cctgctgttt ggcttaacac atctcaaccc ctctgcaaaag cttttattgt  
 cacagatgaa gacatcagga aacaggaaga gcgagtacag caagtacgca agaaattgga  
 agaagcactg atggcagaca tcttgtcgcg agctgctgat acagaagaga tggatatgga  
 aatggacagt ggagatgaag cctaagaata tgatcaggta actttcgacc gactttcccc  
 aagrgaaaat tcctagaat tgaaacaaaa tgtttccact ggcttttgcc tgtaagaaaa  
 aaaatgtacc cgagcacata gagcttttta atagcactaa ccaatgcctt tttagatgta  
 tttttgatgt atatatctat tattcaaaaa atcatgttta ttttgagtcc taggacttaa  
 aattagtctt ttgtaatc aagcaggacc ctaagatgaa gctgagcctt tgatgccagg  
 tgcaatctac tggaaatgta gcacttacgt aaacatttg tttccccac agttttaata  
 agaacagatc aggaattcta aataaattc ccagttaaag attattgtga cttcactgta  
 tataaacata tttttact ttattgaaag gggacacctg tacattcttc catcatcact  
 gtaagacaa ataatgatt atattcaca aaaaaaaa aaaaa 3'

SEQ ID NO:1



21/50

MRAHPGGRCCEEEGESAAAGSGAGGDSAIEQGGQSALAPSPVSGVR  
REGARGGGRGRWKQAGRGGVCGRGRGRGRGRGRGRGRGRPPSG  
GSGLGDDGGCGGGGAPRRPVPFPSSAGPGRGPRAATESGKRM  
DCPALPPGWKKEEVIRKSGLSAGKSDVYFSPSGKKFRSKPQLARYLGNT  
VDLSSFDFRTGKMMPSKLQKNKQRLRNDPLNQNKGKPDLNTTLPIRQTAS  
IFKQPVTKVTNHPSNVKSDPQRMNEQPRQLFWEKRLQGLSASDVTEQII  
KTMELPKGLQGVGPGSNDETLLSAVASALHTSSAPITGQVSAAVEKNPAV  
WLNTSQPLCKAFIVTDEDIRKQEEERVQQVRKKLEALMADILSRAADTEE  
MDIEMDSGDEA

SEQ ID NO:2

FIG. 1

22/50

5' agcgggccga ggagccgggc gcaatggagc ggaagaggctg ggagtgcccg gcgctcccg  
agggctggga gaggaagaa gtgccagaa ggtcggggct gtcgccggc cacagggatg  
tctttacta tagccgagc gggaagaagt tccgagcaa gccgagctg gcgctacc  
tgggcggtc catggacctg agcaccttcg acttcgcac gggcaagatg ctgatgagca  
agatgaacaa gagccgccag cgcgtgcgt acgactctc caaccaggtc aaggcgaagc  
ccgacctgaa cacggcgctg cccgtgcgc agacggcgctc catctcaag cagccggtga  
ccaagattac caaccaccc agcaacaagg tcaagagcga ccgcagaag gcggtggacc  
agccgcgcca gctcttctgg gagaagaagc tgagcgccct gaacgcctc gacattgctg  
aggagctggt caagaccatg gacctccca agggcctgca ggggtggga cctggctgca  
cggatgagac gctgctgtcg gccatcgcca gcgccctgca cactagcacc atgccatca  
cgggacagct ctcgccgcc gtggagaaga acccgcgct atggctcaac accacgcagc  
ccctgtgcaa agccttcatg gtgaccgacg aggacatcag gaagcaggaa gagctggtgc  
agcaggctcg gaagcggctg gaggaggcg tgatggcga catgctggcg cacgtggagg  
agctggccc tgacggggag gcgcgctgg acaaggcctg cgctgaggac gacgacgagg  
aagacgagga ggaggaggag gaggagccc agccggacc ggagatggag cacgtctagg  
gcagaggccc tgccgagagc ccgtgctgcc tgctggagcc gcctgcagac gcggtcctcg  
gccccacgtg aaccaggctc ggcggcgaag ccagccttg gagacacca ggaggaaaggc  
cgtgctcctg gctccctct cggcccgctc ccacttccg gggcctcggg gcacacagct  
ggggctgcc cacccgaaa gacctccac gctcgtctc tacagagtcc ggcttcggga  
agtgcgggt gctcctgggc cctgcctggc tccctacgac ctttgggctc gaggccagct

06-035

23/50

cctccccatg cccgctgtcc cagctccttg agactggaga gcagccagca ggtgccccgc  
agctcggcgc cacggcttgc tgacagctgg gaggtttctt cggctctggag gcgtagtctt  
gaaactcaca tcaccactg tgcagcgtga ggacgggact ctggtctgct gtggggggca  
tgcaggacgg cgccactctc tgccctgcca tgcggctggg ggtgccacag agcctcacgc  
tgccctgagtg gcgtgcccag ggaggccgct ctccctcagt aaatgtaaca cagtcgaggc  
acgtcatcgg gcagccttcc ctgtgtgcca acgccagcct tcgcttctga aaacaaact  
ccagccgctg ccagtcggga ctbtggtcgc cggcgctgcc agaatgctcc actgccagcc  
ggccccccctg cctcggttcc cctctgttt agtggcgaca caggcaccca gcttgggggt  
ggtgctgacg ctcccagggg tgcaggaggc cactgggaca ggtgaggct ccagacgct  
cctcgagggtg ccagctctc cagggagctt ctggcccaag gcgttcttga gggatctgct  
ccttaacccc ccagtgcctt ggcgagggca ggttccaagc cacagacgcc tgccccgagt  
ggactttgcg gccagtccct ggtgacctc ctgggcccctg ctgcccagt gaggttctct  
aacgggtggg ttcawtggcc tgcccavagc gagccccac ctgcattgac cttagggcca  
tagagagggc ctgtcccggg gctgccccag ccaaggatct ggtcgctgcc ccagggggac  
tgatgggcaa gagtgcctcc tgtggctgga ctgtgacct ctctgatggg gcctgaccgc  
gggagctgag gaagcgccgc tccaccgtct gccctccaag gaccgcctg gaggcagtgg  
gctggcagct tcctgtgct tcctgtcaga gtcaaaagcac aaatccctcag gacgggctca  
agggccaggg cagccgaggg aagctccagg tggggaccac gtcttcttga ggttggtgcc  
cactggctgg gacctttgc agtggggtgg cctccccctc gtctgcctgg tggagggagc  
cgtgggcgtg gggacgtgac tgaataaagc caccatgggt ggatgtgctt gg 3'

SEQ ID NO:3

-9E

24/50

MERKRWECPALPQGWEREVEVPRRSGLSAGHRDVFYYSPSGKKFRSKPQOLA  
RYLGGSMDLSTFDERTGKMLMSKMNKSQRQVRDYDSSNQVKGKPDNLNTALP  
VRQTASIFKQPVTKITNHPSNVKSDPPQKAVDQPRQLFWEKKLSGLNAFD  
IAEELVKTMDLPKGLQGVGPGCTDETLLSAIAASALHTSTMPITGQLSAAV  
EKNPGVWLNTTQPLCKAFMVTDEDIRKQEELVQQVRKRLEEALMADMLAH  
VEELARDGEAPLDKACAEDDDEDEEEEEPPDPPEMEHV

SEQ ID NO:4

昨日

## Lipman-Pearson Protein Alignment

Ktuple: 2; Gap Penalty: 4; Gap Length Penalty: 12

Seq1(1>411)	Seq2(1>291)	Similarity	Gap	Gap	Consensus
human dMTase1 protein	human dMTase2 protein	Index	Number	Length	Length
(148>397)	(4>253)	76.0	0	0	250
(148>397)	(4>253)	76.0	0	0	250
v150	v160	v170	v180	v190	v200
					v210
KRMDCPALPPGNKKEEVIRKSGLSAGKSDVYFSPSGKKFRSKPQLARYLGNIVDLSSFDFTIGKMMPSK					
KR : CPALP.GW. : EEV R: SGLSAG. . DV: Y: SPSGKKFRSKPQLARYLG. : : DLS: FDFRTIGKM: SK					
KRWECPALPQGWEREFEVPRRSGLSAGHRDVFYSPSGKKFRSKPQLARYLGGSMDSLTFDFRTIGKMLMSK					
^10	^20	^30	^40	^50	^60
					^70
v220	v230	v240	v250	v260	v270
					v280

LQKNKQRLRNDPLNQNKGKPDNLNTLPIRQTASTIFKQPVTKVINHPNKNVKSDFQRMNEQPRQLFWEKRL  
 : : K: : QR: R D: NQ KGKPDNLN: LP: RQTASTIFKQPVTK: TNHPNKNVKSDFQ: : QPRQLFWEK: L  
 MNKSRQVRVDSSNQKGKPDNLNTALPVRQTASTIFKQPVTKITNHPNKNVKSDFQKAVDQPRQLFWEKKL  
 ^80 ^90 ^100 ^110 ^120 ^130 ^140

FEF - 96

25/50

26/50

v290 v300 v310 v320 v330 v340 v350  
 QGLSASDVTEQIIKIMELPKGLQGVGPGSNDITLLSAVASALHTSSAPITIGQVSAAVEKNPAWLNITSQP  
 GL:A D::E::KIM:L PKGLQGVGPG..DEITLLSA:ASALHTS: PITGQ:SAAVEKNP:VWLNIT:QP  
 SGLNAFDIAEELVKITMDL PKGLQGVGPGCTDEITLLSAIASALHTSIMPITIGQLSAAVEKNPGWLNITIQP  
 ^150 ^160 ^170 ^180 ^190 ^200 ^210

v360 v370 v380 v390  
 LCKAFIVTDEDIRKQEEERVQQVRKKLEFALMADILSRAAD  
 LCKAF:VITDEDIRKQEE VQQVRK:LEEFALMAD:L::...:  
 LCKAFMVITDEDIRKQEEELVQQVRKRLLEFALMADMLAHVEE  
 ^220 ^230 ^240 ^250

FEEL - 9H



# Mouse DNA demethylase-dMTase1 and predicted amino acid sequence

5' **gagccggctg gggagggggc ggatgcgcg tggatgcgcg cgcaccggg tggatgcgcg cgcaccggg** tggatgcgcg cgcaccggg  
 agcaggagga gggggagagc gcggcgggagc gcggcgggagc gcggcgggagc gcggcgggagc gcggcgggagc gcggcgggagc  
 agcaggggggg ccagggcagc gcgctcgctc gcgctcgctc gcgctcgctc gcgctcgctc gcgctcgctc gcgctcgctc  
 gcgctcgggg gcgcgccgt gcgcgggggc gcgcgggggc gcgcgggggc gcgcgggggc gcgcgggggc gcgcgggggc  
 tctgtggccg tggccgtggc cgtggccggg cgtggccggg cgtggccggg cgtggccggg cgtggccggg cgtggccggg  
 gccgcggccg tcccagagt gccgcggcgc gccgcggcgc gccgcggcgc gccgcggcgc gccgcggcgc gccgcggcgc  
 gcggctgcgc cgtcggcagc cgtcggcagc cgtcggcagc cgtcggcagc cgtcggcagc cgtcggcagc cgtcggcagc  
 cgtcggggag ctcggggccg ctcggggccg ctcggggccg ctcggggccg ctcggggccg ctcggggccg ctcggggccg  
 tggactgccc ggcctcccc ggcctcccc ggcctcccc ggcctcccc ggcctcccc ggcctcccc ggcctcccc  
 tcagtgcctg caagagcgat gtctactact gtctactact gtctactact gtctactact gtctactact gtctactact  
 aacctcagct ggcaagatag ctgggaaatg ctgttgacct ctgttgacct ctgttgacct ctgttgacct ctgttgacct  
 ccggcaagat gatgcctagt aaattacaga agaacaagca gagactccgg gagactccgg gagactccgg gagactccgg  
 tcaatcagaa caagggtaaa ccagacctga acacaacatt gccaataga gccaataga gccaataga gccaataga  
 caattttcaa gcaaccagta accaaattca cgaaccacc gagcaataag gagcaataag gagcaataag gagcaataag  
 acccccagcg gatgaatgaa caaccacgtc agcttttctg ggagaagagg ggagaagagg ggagaagagg ggagaagagg  
 ttagcgcatac agatgtaaca gaacaaatta taaaaccat ggagctacct aaaggctctc aaaggctctc aaaggctctc  
 aaggagtcgg tccaggtagc aatgacgaga cccttctgtc cccttctgtc cccttctgtc cccttctgtc cccttctgtc

27/50

28/50

acacaagctc tgcgcccatc acaggacaag tctctgctgc cgtggaaaag aaccctgctg  
tttggttaa cacatctcaa ccctctgca aagctttcat tggtacagat gaagacatta  
ggaaacagga agagcgagtc caacaagtac gcaagaaact ggaggaggca ctgatggccg  
acatcctgtc ccgggctgcg gacacggagg aagtagacat tgacatggac agtggagatg  
aggcgtaaaga atatgatacag gtaactttcg actgaccttc ccaagagca aattgctaga  
aacagaatta aaacatttcc actgggttcc gcctgtaaga aaagtgtac ctgagcacat  
agctttttaa tagcactaac caatgccttt ttagatgtat ttttgatgta tatacttatt  
attccaaatg atgtttattt tgaatcctag gacttaaaat gagtctttta taatagcaag  
cagggccctt ccggtgcagt gcagctttga ggccagggtgc agtctactgg aaaggtagca  
cttacgtgaa atatttgttt cccccacagt tttaataata acagatcagg agtaccaaat  
aagtttccca attaaagatt attatacttc actgtatata aacagatttt tatactttat  
tgaaagaaga tacctgtaca ttcttccatc atcactgtaa agacaaataa atgactatat  
tcac 3'

SEQ ID NO: 5

7-11-91

29/50

MRAHPGGGCCPEQEEGESAAAGSGAGGDSAIEQGGQSALAPSPVSGVR  
REGARGGGRGRWKQAARGGVCGRGRGRGRGRGRGRGRGRGPQSG  
GSLGGDGGGAGGCGVSGGVA PRDPVPFPSSGPGPRGPRATESG  
KRMDCPALPPGWKKEEVIRKSLSAGKSDVYFSPSGKKFRSKPQLARYL  
GNAVDLSSFDFRTGKMMP SKLQKNKQRLRNDPLNQNKGKPD LNTTLPIRQ  
TASIFKQPVTFTNHPSNKVKSDPQRMNEQPRQLFWEKRLQGLSASDVTE  
QIIKTME L PKGLQGVGPGSND ETL LSAVASALHTSSAPITGQVSAAVEKN  
PAVWLNTS QPLCKAFIVTDEDIRKQEE RVQQVRKKL EEALMADILSRAAD  
TEEV D I D M D S G D E A

SEQ ID NO: 6

715 OK

# Mouse DNA demethylase-dMTase2 and predicted amino acid sequence

5' cacgcgcggg cgggtgggcg gagcgcccc ctagcgggg gctgtgaagc gcggggagggg  
 ggccgagcgg gtggcgaagc cggcgcgcg cgggctgggg gcggagggcg gagggccgtg  
 ggacagaaca gctgcggcga gtggcgggcg cggagggagc cgaatcggcg acgagcccg  
 gggtcgcaac ttgcagaagc ggcgcgggcg gcggcatcgg ccacggcggg cggaagaagcc  
 gggcgcaat ggagcggag agtgggagt gccggcgct ccgcagggc tgggaaaggg  
 aagaagtgc caggaggtcg gggctgtcgg ccggccacag ggatgtcttt tactatagcc  
 ccagcgggaa gaagtccgc agcaagccac aactggcacg ttacctgggc ggatccatgg  
 acctcagcac cttcgacttc cgcaccggaa agatgttgat gaacaagatg aataagagtc  
 gccagcgtgt gcgctatgat tcttccaacc aggtcaaggg caagcctgac ctgaacacccg  
 cgctgcctgt acggcagact gcattccatct tcaagcaacc ggtgaccaag ataccaaac  
 accccagcaa caaggtcaag agcgaccgc agaaggcagt ggaccagccg aggcagcttt  
 tctgggagaa gaagctaagt ggattgagt cctttgacat tgcagaagaa ctggtcagga  
 ccatggactt gccaaagggc ctgcagggag tgggccctgg ctgtacagat gagacgctgc  
 tgtcagccat tgcgagtgt ctacacacca gcaccctgcc cattacaggc cagctctctg  
 cagccgtgga gaagaaccct ggtgtgtggc tgaacactgc acagccactg tgcaaaagcct  
 tcatggtgac agatgacgac atcaggaagc aggaggagct ggtacagcag gtacggaagc  
 gcctggagga ggcactgat gccacatgc tagctcatgt ggaggagctt gcccgagacg  
 gggaggcacc actggacaag gcctgtgcag aggaggaaga ggaggaggaa gaggaggagg

30/50



31/50

aagagccgga gccagagcga gtgtagcaca ggtgccctgc ccaagtctgg gctgcagact  
gccttcagcc ttgcctggac caggtagggg ccagacctgt aggaggcagc cgtccacctc  
ctttccaaag cctcctgctt ccaggctca gtgcaggag ccctgtgga ccttgaactc  
acttgtccct gcgctgcctg gcaggaaagg ccacactgaa agcagatgag cagtgaacca  
actgagaggc cacctggaca cagtcacctc cctgcctcct tatcatagga caaggccttg  
cttggcaccg aggagctggg agccgtgttg ggtgctggag gaagtctctg gaaacacacc  
tggctatgcc caccttatgt ccctaaggct attacaggcc agggtttggg ctgctcggc  
ccacagggct gccagcctc ccacactga ggtcagcag ccaccaggga agtcactttc  
cttcaataaa ctgatggtag gaacttgtag 3'

SEQ ID NO: 7

FEEL - 9M



Lipman-Pearson Protein Alignment

Ktuple: 2; Gap Penalty: 4; Gap Length Penalty: 12

Seq1(1>414) Seq2(1>285)

mouse dMTase1 protein	mouse dMTase2 protein	Similarity Index	Gap Number	Gap Length	Consensus Length
(151>400)	(4>253)	75.2	0	0	250
(151>400)	(4>253)	75.2	0	0	250

v160 v170 v180 v190 v200 v210 v220

KRMDCPALPPGWNKEEVIRKSGLSAGKSDVYFSPSGKKFRSKPQLARYLGNVAVDLSSFDERTGKMMPSK

KR : CPALP.GW.:EEV R:SGLSAG..DV:Y:SPSGKKFRSKPQLARYLG.:DLS:FDERTGKM: :K

KRWECPALPQGWEREVEVPRRSGLSAGHRDVFYSPSGKKFRSKPQLARYLGGSMIDLSTFDERTGKMLMNK

33/50

^10 ^20 ^30 ^40 ^50 ^60 ^70

v230 v240 v250 v260 v270 v280 v290

LQKNKQRLRNDPLNQNGKGPDLNTTLPIRQQTASIFKQPVTKFTNHPSNKKVKSDPQRMNEQPRQLFWEKRL

:K::QR:R D: NQ KGKPDINT:LP:RQTASIFKQPVTK:TNHPSNKKVKSDPQ: :QPRQLFWEK:L

MNKSQRVRYDSSNQVKGKPDINTALPVRQQTASIFKQPVTKFTNHPSNKKVKSDPQKAVDQPRQLFWEKKL

^80 ^90 ^100 ^110 ^120 ^130 ^140

FE-90

34/50


v300 v310 v320 v330 v340 v350 v360  
 QGLSASDVTEQIIKIMELPKGLQGVGPGSNDITLLSAVASALHTSSAPITIGQVSAAVEKNPAAVWLNTSQP  
 GLSA D::E:::TM:LPGGLQGVGPG..DEITLLSA:ASALHTS: PITIGQ:SAAVEKNP:VWLNT:QP  
 SGLSAFDIAEEELVRIMDLPKGLQGVGPGCTDEITLLSAIASALHTSITLPTIGQLSAAVEKNPVGWLNTAQP  
 ^150 ^160 ^170 ^180 ^190 ^200 ^210

v370 v380 v390 v400  
 LCKAFIVTDEDIRKQEEERVQQVRKKLEEFALMADILSRAAD  
 LCKAF:VTD:DIRKQEE VQQVRK:LEEFALMAD:L:::..  
 LCKAFMVTDDDIRKQEEELVQQVRKRLLEEFALMADMLAHVEE  
 ^220 ^230 ^240 ^250

T E S - 9 P



35/50



mistrime  
dMTase







FIG. 10A


36/50

FIG. 10B


37/50




38/50

FIG. 11A

39/50



40/50

FIG. 11F

41/50





Fig. 12A - Origin

42/50

FIG. 12B





43/50





FIG. 13A






FIG. 13B

44/50


FIG. 13C

45/50

dMTase



18s



dMTase / 18s







FIG. 130

46/50

FIG. 14A

47/50

FIG. 14BFIG. 14C

48/50







Fig. 15

49/50

Fig. 16

50/50





## SEQUENCE LISTING

<110> MCGILL UNIVERSITY  
 SZYF, Moshe  
 BHATTACHARYA, Sanjoy K.  
 RAMCHANDANI, Shyam

<120> DNA DEMETHYLASE, THERAPEUTIC AND  
 DIAGNOSTIC USES THEREOF

<130> 1770-183"PCT" FC/ld

<150> CA 2,220,805

<151> 1997-11-12

<150> CA 2,230,991

<151> 1998-05-11

<160> 10

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 1804

<212> DNA

<213> Unknown

<400> 1

ccgctctgcg	ggcggggcgg	gtctccggga	ttccaagggc	tcggttacgg	aagaagcgca	60
gagccggctg	gggagggggc	tggatgcgcg	cgcacccggg	gggaggccgc	tgctgcccgg	120
agcaggagga	gggggagagc	gcggcgggcg	gcagcggcgc	tggcggcgac	tccgccatag	180
agcagggggg	ccagggcagc	gcgctcgctc	cgtccccggg	gagcggcgctg	cgcaggggaag	240
gcgctcgggg	cggcgggcgt	ggccgggggc	ggtggaagca	ggcggcccgg	ggcggcgggc	300
tctgtggccg	tggccgtggc	cgtggccggg	gtcggggccg	tggccggggc	cggggccggg	360
gccgcggccg	tcccagagt	ggcggcagcg	gccttgggcg	cgacggcggc	ggcggcgcg	420
gcggctgcgg	cgctcggcagc	ggtggcgggc	tcgcccccg	gcgggaccc	gtccctttcc	480
cgctcggggag	ctcgggggccg	ggggccagg	gaccccgggc	cacggagagc	gggaagagga	540
tggactgccc	ggccctcccc	cccggatgga	agaaggagga	agtgatccga	aaatcagggc	600
tcagtgtctg	caagagcgat	gtctactact	tcagtccaag	tggtaagaag	ttcagaagta	660
aacctcagct	ggcaagatac	ctgggaaatg	ctgttgacct	tagcagtttt	gacttcagga	720
ccggcaagat	gatgcctagt	aaattacaga	agaacaagca	gagactccgg	aatgaccccc	780
tcaatcagaa	caagggtaaa	ccagacctga	acacaacatt	gccaattaga	caaactgcat	840
caattttcaa	gcaaccagta	accaaattca	cgaaccaccc	gagcaataag	gtgaagtcag	900
acccccagcg	gatgaatgaa	caaccacgtc	agcttttctg	ggagaagagg	ctacaaggac	960
ttagcgcatc	agatgtaaca	gaacaaatta	taaaaaccat	ggagctacct	aaaggtcttc	1020
aaggagtcgg	tccaggtagc	aatgacgaga	cccttctgtc	tgctgtggcc	agtgtcttac	1080
acacaagctc	tgcgcccatc	acaggacaag	tctctgtctg	cgtggaaaag	aaccctgctg	1140
tttggtctaa	cacatctcaa	cccctctgca	aagctttcat	tggtacagat	gaagacatta	1200
ggaaacagga	agagcgagtc	caacaagtac	gcaagaaact	ggaggaggca	ctgatggccg	1260
acatcctgtc	ccgggctgcg	gacacggagg	aagtagacat	tgacatggac	agtggagatg	1320
aggcgtaaga	atatgatcag	gtaactttcg	actgaccttc	cccaagagca	aattgctaga	1380
aacagaatta	aaacatttcc	actgggtttc	gcctgtaaga	aaaagtgtac	ctgagcacat	1440
agctttttaa	tagcactaac	caatgccttt	ttagatgtat	ttttgatgta	tatatctatt	1500
attccaaatg	atgtttatgt	tgaatcctag	gacttaaaat	gagtccttta	taatagcaag	1560
cagggccctt	ccggtgcagt	gcagcttttg	ggccaggtgc	agtctactgg	aaaggtagca	1620
cttacgtgaa	atatttggtt	ccccacagt	tttaataata	acagatcagg	agtaccaa	1680

aagtttccca attaaagatt attatacttc actgtatata aacagatttt tatactttat 1740  
 tgaaagaaga tacctgtaca ttcttccatc atcactgtaa agacaaataa atgactatat 1800  
 tcac 1804

<210> 2  
 <211> 411  
 <212> PRT  
 <213> Unknown

<400> 2  
 Met Arg Ala His Pro Gly Gly Gly Arg Cys Cys Pro Glu Gln Glu Glu  
 1 5 10 15  
 Gly Glu Ser Ala Ala Gly Gly Ser Gly Ala Gly Gly Asp Ser Ala Ile  
 20 25 30  
 Glu Gln Gly Gly Gln Gly Ser Ala Leu Ala Pro Ser Pro Val Ser Gly  
 35 40 45  
 Val Arg Arg Glu Gly Ala Arg Gly Gly Gly Arg Gly Arg Gly Arg Trp  
 50 55 60  
 Lys Gln Ala Gly Arg Gly Gly Gly Val Cys Gly Arg Gly Arg Gly Arg  
 65 70 75 80  
 Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg  
 85 90 95  
 Pro Pro Ser Gly Gly Ser Gly Leu Gly Gly Asp Gly Gly Gly Cys Gly  
 100 105 110  
 Gly Gly Gly Ser Gly Gly Gly Gly Ala Pro Arg Arg Glu Pro Val Pro  
 115 120 125  
 Phe Pro Ser Gly Ser Ala Gly Pro Gly Pro Arg Gly Pro Arg Ala Thr  
 130 135 140  
 Glu Ser Gly Lys Arg Met Asp Cys Pro Ala Leu Pro Pro Gly Trp Lys  
 145 150 155 160  
 Lys Glu Glu Val Ile Arg Lys Ser Gly Leu Ser Ala Gly Lys Ser Asp  
 165 170 175  
 Val Tyr Tyr Phe Ser Pro Ser Gly Lys Lys Phe Arg Ser Lys Pro Gln  
 180 185 190  
 Leu Ala Arg Tyr Leu Gly Asn Thr Val Asp Leu Ser Ser Phe Asp Phe  
 195 200 205  
 Arg Thr Gly Lys Met Met Pro Ser Lys Leu Gln Lys Asn Lys Gln Arg  
 210 215 220  
 Leu Arg Asn Asp Pro Leu Asn Gln Asn Lys Gly Lys Pro Asp Leu Asn  
 225 230 235 240  
 Thr Thr Leu Pro Ile Arg Gln Thr Ala Ser Ile Phe Lys Gln Pro Val  
 245 250 255  
 Thr Lys Val Thr Asn His Pro Ser Asn Lys Val Lys Ser Asp Pro Gln  
 260 265 270  
 Arg Met Asn Glu Gln Pro Arg Gln Leu Phe Trp Glu Lys Arg Leu Gln  
 275 280 285  
 Gly Leu Ser Ala Ser Asp Val Thr Glu Gln Ile Ile Lys Thr Met Glu  
 290 295 300  
 Leu Pro Lys Gly Leu Gln Gly Val Gly Pro Gly Ser Asn Asp Glu Thr  
 305 310 315 320  
 Leu Leu Ser Ala Val Ala Ser Ala Leu His Thr Ser Ser Ala Pro Ile  
 325 330 335  
 Thr Gly Gln Val Ser Ala Ala Val Glu Lys Asn Pro Ala Val Trp Leu  
 340 345 350  
 Asn Thr Ser Gln Pro Leu Cys Lys Ala Phe Ile Val Thr Asp Glu Asp  
 355 360 365

Ile Arg Lys Gln Glu Glu Arg Val Gln Gln Val Arg Lys Lys Leu Glu  
 370 375 380  
 Glu Ala Leu Met Ala Asp Ile Leu Ser Arg Ala Ala Asp Thr Glu Glu  
 385 390 395 400  
 Met Asp Ile Glu Met Asp Ser Gly Asp Glu Ala  
 405 410

<210> 3  
 <211> 1589  
 <212> DNA  
 <213> Unknown

<400> 3  
 cacgcgcggg cgggtgggcg gagcggcccc cctagcgggg gctgtgaagc gcggggaggg 60  
 ggccgagcgg gtggcgaagc cggcgcgcg cgggtgggg gcggaggggc gagggccgtg 120  
 ggacagaaca gctgcggcga gtggcggcgg cggaggggagc cgaatcggcg acgagcccgg 180  
 gggtcgcaac ttgcagaagc ggcggcgggc gcggcatcgg ccacggcggg cggaaaagcc 240  
 ggggcgcaat ggagcggag aggtgggagt gcccggcgct cccgcagggc tgggaaaggg 300  
 aagaagtgcc caggaggtcg gggctgtcgg ccggccacag ggatgtcttt tactatagcc 360  
 ccagcgggaa gaagtccgc agcaagccac aactggcacg ttacctgggc ggatccatgg 420  
 acctcagcac cttcgacttc cgcaccggaa agatgttgat gaacaagatg aataagagtc 480  
 gccagcgtgt gcgctatgat tcttccaacc aggtcaaggc caagcctgac ctgaacaccg 540  
 cgctgcctgt acggcagact gcatccatct tcaagcaacc ggtgaccaag atcaccaacc 600  
 accccagcaa caaggtcaag agcgacccgc agaaggcagt ggaccagccg aggcagcttt 660  
 tctgggagaa gaagctaagt ggattgagt cctttgacat tgcagaagaa ctggtcagga 720  
 ccatggactt gcccaggggc ctgcaggag tgggccctgg ctgtacagat gagacgctgc 780  
 tgtcagccat tgcagtgct ctacacacca gcaccctgcc cattacaggc cagctctctg 840  
 cagccgtgga gaagaacct ggtgtgtggc tgaacactgc acagccactg tgcaaaacct 900  
 tcatggtgac agatgacgac atcaggaagc aggaggagct ggtacagcag gtacggaagc 960  
 gcctggagga ggcactgatg gccgacatgc tagctcatgt ggaggagctt gcccagagacg 1020  
 gggaggcacc actggacaag gcctgtgcag aggaggaaga ggaggaggaa gaggaggagg 1080  
 aagagccgga gccagagcga gtgtagcaca ggtgccctgc ccaagtctgg gctgcagact 1140  
 gccttcagcc ttgcctggac caggtagggg ccagacctgt aggaggcagc cgtccacctc 1200  
 ctttccaaag cctcctgctt ccagggtctca gtgcagggag cccctgtgga ccttgaactc 1260  
 acttgtccct gcgctgcctg gcaggaagcc ccactgaa agcagatgag cagtgaacca 1320  
 actgagaggc cacctggaca cagtcacctc cctgcctcct tatcatagga caaggccttg 1380  
 cttggcaccg aggagctggg agccgtgttg ggtgctggag gaagtttctg gaaacacacc 1440  
 tggctatgcc caccttatgt ccctaaggct attacaggcc agggtttgga ctgctccggc 1500  
 ccacagggct gcccagcctc cccactga gggtcagcag cccaccagga agtcactttc 1560  
 cttcaataaa ctgatggtag gaacttgtg 1589

<210> 4  
 <211> 291  
 <212> PRT  
 <213> Unknown

<400> 4  
 Met Glu Arg Lys Arg Trp Glu Cys Pro Ala Leu Pro Gln Gly Trp Glu  
 1 5 10 15  
 Arg Glu Glu Val Pro Arg Arg Ser Gly Leu Ser Ala Gly His Arg Asp  
 20 25 30  
 Val Phe Tyr Tyr Ser Pro Ser Gly Lys Lys Phe Arg Ser Lys Pro Gln  
 35 40 45  
 Leu Ala Arg Tyr Leu Gly Gly Ser Met Asp Leu Ser Thr Phe Asp Phe  
 50 55 60  
 Arg Thr Gly Lys Met Leu Met Ser Lys Met Asn Lys Ser Arg Gln Arg  
 65 70 75 80

Val Arg Tyr Asp Ser Ser Asn Gln Val Lys Gly Lys Pro Asp Leu Asn  
 85 90 95  
 Thr Ala Leu Pro Val Arg Gln Thr Ala Ser Ile Phe Lys Gln Pro Val  
 100 105 110  
 Thr Lys Ile Thr Asn His Pro Ser Asn Lys Val Lys Ser Asp Pro Gln  
 115 120 125  
 Lys Ala Val Asp Gln Pro Arg Gln Leu Phe Trp Glu Lys Lys Leu Ser  
 130 135 140  
 Gly Leu Asn Ala Phe Asp Ile Ala Glu Glu Leu Val Lys Thr Met Asp  
 145 150 155 160  
 Leu Pro Lys Gly Leu Gln Gly Val Gly Pro Gly Cys Thr Asp Glu Thr  
 165 170 175  
 Leu Leu Ser Ala Ile Ala Ser Ala Leu His Thr Ser Thr Met Pro Ile  
 180 185 190  
 Thr Gly Gln Leu Ser Ala Ala Val Glu Lys Asn Pro Gly Val Trp Leu  
 195 200 205  
 Asn Thr Thr Gln Pro Leu Cys Lys Ala Phe Met Val Thr Asp Glu Asp  
 210 215 220  
 Ile Arg Lys Gln Glu Glu Leu Val Gln Gln Val Arg Lys Arg Leu Glu  
 225 230 235 240  
 Glu Ala Leu Met Ala Asp Met Leu Ala His Val Glu Glu Leu Ala Arg  
 245 250 255  
 Asp Gly Glu Ala Pro Leu Asp Lys Ala Cys Ala Glu Asp Asp Asp Glu  
 260 265 270  
 Glu Asp Glu Glu Glu Glu Glu Glu Pro Asp Pro Asp Pro Glu Met  
 275 280 285  
 Glu His Val  
 290

<210> 5  
 <211> 1966  
 <212> DNA  
 <213> Unknown

<400> 5  
 gggggcggtg ccccgagaag gcggagacaa gatggccgcc catagcgctt ggaggacctt 60  
 agaggcggtg gccggggcca cgccccgggc aggagggccg ctctgtgcgc gcccgctcta 120  
 tgatgcttgc gcgcgtcccc cgcgcgccgc gctgcgggcg gggcggttct ccgggattcc 180  
 aagggtcgg ttacggaaga agcgcagcgc cggctgggga gggggctgga tgcgcgcgca 240  
 cccgggggga ggccgtgct gcccgagca ggaggagggg gagagtgcgg cggcgggcag 300  
 cggcgctggc ggcgactccg ccatagagca ggggggccag ggcagcgcgc tcgccccgtc 360  
 cccggtgagc ggcgtgcgca gggaaggcgc tcggggcggc ggccgtggcc gggggcggtg 420  
 gaagcaggcg ggccggggcg gcggcgctctg tggccgtggc cggggccggg gccgtggccg 480  
 gggacgggga cggggccggg gccggggccg cggccgtccc ccgagtggcg gcagcggcct 540  
 tggcgcgac ggccggcggt gcggcgcgcg cggcagcggg ggccggcgcg cccccggcg 600  
 ggagccggtc cctttccggt cggggagcgc gggggccggg ccaggggac cccggggcac 660  
 ggagagcggg aagaggatgg attgcccggc cctccccccc ggatggaaga aggaggaagt 720  
 gatccgaaaa tctgggctaa gtgctggcaa gagcgatgtc tactacttca gtccaagtgg 780  
 taagaagttc agaagcaagc ctcagttggc aaggtacctg ggaaatactg ttgatctcag 840  
 cagttttgac ttcagaactg gaaagatgat gcctagtaaa ttacagaaga acaaacagag 900  
 actgcgaaac gatcctctca atcaaaaataa gggtaaacca gacttgaata caacattgcc 960  
 aattagacaa acagcatcaa ttttcaaaca accggttaacc aaagtcacaa atcatcctag 1020  
 taataaagtg aaatcagacc cacaacgaat gaatgaacag ccacgtcagc ttttctggga 1080  
 gaagagcta caaggactta gtgcatcaga tgtaacagaa caaattataa aaaccatgga 1140  
 actaccctaa ggtcttcaag gagttggtcc aggtagcaat gatgagacct ttttatctgc 1200  
 tgttgccagt gctttgcaca caagctctgc gccaatcaca gggcaagtct ccgctgctgt 1260  
 ggaaaagaac cctgctgttt ggcttaacac atctcaacct ctctgcaaag cttttattgt 1320

```

cacagatgaa gacatcagga aacaggaaga gcgagtacag caagtacgca agaaattgga 1380
agaagcactg atggcagaca tcttgctcg agctgctgat acagaagaga tggatattga 1440
aatggacagt ggagatgaag cctaagaata tgatcaggta actttcgacc gactttcccc 1500
aagrgaaaat tcctagaaat tgaacaaaaa tgtttccact ggcttttgcc tgtaagaaaa 1560
aaaatgtacc cgagcacata gagcttttta atagcactaa ccaatgcctt tttagatgta 1620
tttttgatgt atatatctat tattcaaaaa atcatgttta ttttgagtcc taggacttaa 1680
aattagtctt ttgtaatatc aagcaggacc ctaagatgaa gctgagcttt tgatgccagg 1740
tgcaatctac tggaaatgta gcacttacgt aaaacatttg tttccccac agttttaata 1800
agaacagatc aggaattcta aataaaatttc ccagttaaag attattgtga cttcactgta 1860
tataaacata tttttatact ttattgaaag gggacacctg tacattcttc catcatcact 1920
gtaaagacaa ataatgatt atattcacia aaaaaaaaaa aaaaaa 1966

```

<210> 6  
 <211> 414  
 <212> PRT  
 <213> Unknown

<400> 6

```

Met Arg Ala His Pro Gly Gly Gly Arg Cys Cys Pro Glu Gln Glu Glu
1      5      10      15
Gly Glu Ser Ala Ala Gly Gly Ser Gly Ala Gly Gly Asp Ser Ala Ile
20      25      30
Glu Gln Gly Gly Gln Gly Ser Ala Leu Ala Pro Ser Pro Val Ser Gly
35      40      45
Val Arg Arg Glu Gly Ala Arg Gly Gly Arg Gly Arg Gly Arg Trp
50      55      60
Lys Gln Ala Ala Arg Gly Gly Gly Val Cys Gly Arg Gly Arg Gly Arg
65      70      75      80
Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg
85      90      95
Pro Gln Ser Gly Gly Ser Gly Leu Gly Gly Asp Gly Gly Gly Gly Ala
100     105     110
Gly Gly Cys Gly Val Gly Ser Gly Gly Gly Val Ala Pro Arg Arg Asp
115     120     125
Pro Val Pro Phe Pro Ser Gly Ser Ser Gly Pro Gly Pro Arg Gly Pro
130     135     140
Arg Ala Thr Glu Ser Gly Lys Arg Met Asp Cys Pro Ala Leu Pro Pro
145     150     155     160
Gly Trp Lys Lys Glu Glu Val Ile Arg Lys Ser Gly Leu Ser Ala Gly
165     170     175
Lys Ser Asp Val Tyr Tyr Phe Ser Pro Ser Gly Lys Lys Phe Arg Ser
180     185     190
Lys Pro Gln Leu Ala Arg Tyr Leu Gly Asn Ala Val Asp Leu Ser Ser
195     200     205
Phe Asp Phe Arg Thr Gly Lys Met Met Pro Ser Lys Leu Gln Lys Asn
210     215     220
Lys Gln Arg Leu Arg Asn Asp Pro Leu Asn Gln Asn Lys Gly Lys Pro
225     230     235     240
Asp Leu Asn Thr Thr Leu Pro Ile Arg Gln Thr Ala Ser Ile Phe Lys
245     250     255
Gln Pro Val Thr Lys Phe Thr Asn His Pro Ser Asn Lys Val Lys Ser
260     265     270
Asp Pro Gln Arg Met Asn Glu Gln Pro Arg Gln Leu Phe Trp Glu Lys
275     280     285
Arg Leu Gln Gly Leu Ser Ala Ser Asp Val Thr Glu Gln Ile Ile Lys
290     295     300

```

Thr Met Glu Leu Pro Lys Gly Leu Gln Gly Val Gly Pro Gly Ser Asn  
 305 310 315 320  
 Asp Glu Thr Leu Leu Ser Ala Val Ala Ser Ala Leu His Thr Ser Ser  
 325 330 335  
 Ala Pro Ile Thr Gly Gln Val Ser Ala Val Glu Lys Asn Pro Ala  
 340 345 350  
 Val Trp Leu Asn Thr Ser Gln Pro Leu Cys Lys Ala Phe Ile Val Thr  
 355 360 365  
 Asp Glu Asp Ile Arg Lys Gln Glu Glu Arg Val Gln Gln Val Arg Lys  
 370 375 380  
 Lys Leu Glu Glu Ala Leu Met Ala Asp Ile Leu Ser Arg Ala Ala Asp  
 385 390 395 400  
 Thr Glu Glu Val Asp Ile Asp Met Asp Ser Gly Asp Glu Ala  
 405 410

<210> 7  
 <211> 2392  
 <212> DNA  
 <213> Unknown

<400> 7

agcgggcccga	ggagccggggc	gcaatggagc	ggaagaggtg	ggagtgcccg	gcgctcccgc	60
agggctggga	gaggggaagaa	gtgcccagaa	ggtcggggct	gtcggccggc	cacagggatg	120
tcttttacta	tagccccagc	gggaagaagt	tccgcagcaa	gccgcagctg	gcgcgctacc	180
tgggcggctc	catggacctg	agcaccttcg	acttcgcac	gggcaagatg	ctgatgagca	240
agatgaacaa	gagccgccag	cgcgtgcgct	acgactcctc	caaccaggctc	aaggggcaagc	300
ccgacctgaa	cacggcgctg	cccgtgcgcc	agacggcgctc	catcttcaag	cagccgggtga	360
ccaagattac	caaccacccc	agcaacaagg	tcaagagcga	cccgcagaag	gcggtggacc	420
agccgcgcca	gctcttctgg	gagaagaagc	tgagcggcct	gaacgccttc	gacattgctg	480
aggagctggt	caagaccatg	gacctcccca	agggcctgca	gggggtggga	cctggctgca	540
cggatgagac	gctgctgtcg	gccatcgcca	gcgccttgca	cactagcacc	atgccccatca	600
cgggacagct	ctcggccgcc	gtggagaaga	accccggcgt	atggctcaac	accacgcagc	660
ccctgtgcaa	agccttcatg	gtgaccgacg	aggacatcag	gaagcaggaa	gagctggtgc	720
agcaggtgcg	gaagcggctg	gaggaggcgc	tgatggccga	catgctggcg	cacgtggagg	780
agctggcccc	tgacggggag	gcgcgcgtgg	acaaggcctg	cgctgaggac	gacgacgagg	840
aagacgagga	ggaggaggag	gaggagcccc	acccggaccc	ggagatggag	cacgtctagg	900
gcagaggccc	tgccgagagc	ccgtgctgcc	tgctggagcc	gcctgcagac	gcggtcctcg	960
gccccacgtg	aaccaggctc	ggcggcgaa	cccagccttg	gagacaccca	ggaggaaggc	1020
cgtgctcctg	gctccctcct	cggcccgtcc	ccacttcccg	gggcctcggg	gcacacagct	1080
ggggctgccc	ccaccgaaa	gaccctccac	gctcgtcctc	tacagagtcc	ggcttcggga	1140
agtgcggggt	gctcctgggc	cctgcctggc	tccctacgac	ctttgggctc	gaggccagct	1200
cctccccatg	cccgtgtgcc	cagctccttg	agactggaga	gcagccagca	ggtgcccggc	1260
agctcggcgc	cacggcttgc	tgacagctgg	gagggtttct	cggctctggag	gcgtagtgtt	1320
gaaactcaca	tcacccactg	tgacagctga	ggacgggact	ctggctctgct	gtggggggca	1380
tgcaggacgg	cgccactctc	tgccctgcc	tgcggtgggt	ggtgccacag	agcctcaccg	1440
tgccctgagtg	gcgtgcccag	ggaggcgcgt	ctccttcagt	aaatgtaaca	cagtcgaggc	1500
acgtcatcgg	gcagccttcc	ctgtgtgcca	acgccagcct	tcgcttctga	aaaccaaact	1560
ccagccgctg	ccagtcggga	cttggtcgcc	cggcgctgcc	agaatgctcc	actgccagcc	1620
ggccccccctg	cctcggtttc	ccttctgttt	agtggcgaca	caggcaccga	gctttgggggt	1680
ggtgctgacg	ctcccagggg	tgccaggagc	cactgggaca	gggtgaggct	cccagacgct	1740
cctcgagggtg	cccagctctc	cagggagctt	ctggcccaag	gcgttcttga	gggatctgct	1800
ccttaacccc	ccagtgcctt	ggcgagggca	ggttccaagc	cacagacgcc	tgccccgagt	1860
ggacttttgcg	gccagtcctt	gggtgccttc	ctgggccttg	cttgcccagt	gagggttcct	1920
aacgggtggg	ttcawtggcc	tgggccvagg	gagccccac	ctgcattgac	cttagggcca	1980
tagagagggc	ctgtcccggg	gctgccccag	ccaaggatct	ggtcgctgcc	ccagggggac	2040
tgatgggcaa	gagtcgcccc	tgtggctgga	ctgtgaccat	ccctgatggg	gcctgaccgc	2100
gggagctgag	gaagcgccgc	tccaccgtct	gccctccaag	gacccgcatg	gaggcagtg	2160

```

gctggcagct tcttgcctgc ccctgtcaga gtcaaagcac aaatcctcag gacgggctca 2220
agggccaggg cagccgaggg aagctccagg tggggaccac gtcttcctga ggttggtgcc 2280
cactggctgg gaccctttgc agtgggggtg cctcccctct gtctgcctgg tggagggagc 2340
cgtgggcgtg gggacgtgac tgaataaagc caccatgggt ggatgtgctt gg 2392

```

<210> 8  
 <211> 285  
 <212> PRT  
 <213> Unknown

```

<400> 8
Met Glu Arg Lys Arg Trp Glu Cys Pro Ala Leu Pro Gln Gly Trp Glu
 1          5          10          15
Arg Glu Glu Val Pro Arg Arg Ser Gly Leu Ser Ala Gly His Arg Asp
 20          25          30
Val Phe Tyr Tyr Ser Pro Ser Gly Lys Lys Phe Arg Ser Lys Pro Gln
 35          40          45
Leu Ala Arg Tyr Leu Gly Gly Ser Met Asp Leu Ser Thr Phe Asp Phe
 50          55          60
Arg Thr Gly Lys Met Leu Met Asn Lys Met Asn Lys Ser Arg Gln Arg
 65          70          75          80
Val Arg Tyr Asp Ser Ser Asn Gln Val Lys Gly Lys Pro Asp Leu Asn
 85          90          95
Thr Ala Leu Pro Val Arg Gln Thr Ala Ser Ile Phe Lys Gln Pro Val
 100         105         110
Thr Lys Ile Thr Asn His Pro Ser Asn Lys Val Lys Ser Asp Pro Gln
 115         120         125
Lys Ala Val Asp Gln Pro Arg Gln Leu Phe Trp Glu Lys Lys Leu Ser
 130         135         140
Gly Leu Ser Ala Phe Asp Ile Ala Glu Glu Leu Val Arg Thr Met Asp
 145         150         155         160
Leu Pro Lys Gly Leu Gln Gly Val Gly Pro Gly Cys Thr Asp Glu Thr
 165         170         175
Leu Leu Ser Ala Ile Ala Ser Ala Leu His Thr Ser Thr Leu Pro Ile
 180         185         190
Thr Gly Gln Leu Ser Ala Ala Val Glu Lys Asn Pro Gly Val Trp Leu
 195         200         205
Asn Thr Ala Gln Pro Leu Cys Lys Ala Phe Met Val Thr Asp Asp Asp
 210         215         220
Ile Arg Lys Gln Glu Glu Leu Val Gln Gln Val Arg Lys Arg Leu Glu
 225         230         235         240
Glu Ala Leu Met Ala Asp Met Leu Ala His Val Glu Glu Leu Ala Arg
 245         250         255
Asp Gly Glu Ala Pro Leu Asp Lys Ala Cys Ala Glu Glu Glu Glu
 260         265         270
Glu Glu Glu Glu Glu Glu Pro Glu Pro Glu Arg Val
 275         280         285

```

<210> 9  
 <211> 17  
 <212> DNA  
 <213> Unknown

<400> 9  
 ctggcaagag cgatgtc

<210> 10  
<211> 22  
<212> DNA  
<213> Unknown

<400> 10  
agtctgggtt acccttattt tg

22



# INTERNATIONAL SEARCH REPORT

national Application No

PCT/CA 98/01059

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/52 C12N9/00 A61K38/43 C07K16/40 C12N15/11  
A61K48/00 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T/	BHATTACHARYA SK ET AL: "A mammalian protein with specific demethylase activity for mCpG DNA" NATURE, vol. 397, 18 February 1999, pages 579-583, XP002097746 LONDON GB	
P/X	HENDRICH B ET AL: "Identification and characterization of a family of mammalian methyl-CpG binding proteins." MOLECULAR AND CELLULAR BIOLOGY, (1998 NOV) 18 (11) 6538-47. JOURNAL CODE: NGY. ISSN: 0270-7306., XP002097747 United States see the whole document	1-3

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

24 March 1999

Date of mailing of the international search report

08/04/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Espen, J

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 98/01059

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X/	SZYF M. ET AL.: "Mammalian cells contain a general (CpG) DNA demethylating activity" MOLECULAR BIOLOGY OF THE CELL, vol. 4, October 1993, page 74A XP002087767 * abstract 426 *	1
X/	SZYF M ET AL: "Ras induces a general DNA demethylation activity in mouse embryonal P19 cells." J BIOL CHEM, MAY 26 1995, 270 (21) P12690-6, XP002087765 UNITED STATES see the whole document	1
X/	SZYF M: "DNA methylation properties: consequences for pharmacology." TRENDS PHARMACOL SCI, JUL 1994, 15 (7) P233-8, XP002087766 ENGLAND see page 234, right-hand column; figures 1,2	1
X/	WEISS A ET AL: "The role of DNA demethylation during development." GENES TO CELLS, (1997 AUG) 2 (8) 481-6. REF: 35 JOURNAL CODE: CUF. ISSN: 1356-9597., XP002097748 ENGLAND: United Kingdom see figures 3,4	1
X/	WEISS A ET AL: "DNA demethylation in vitro: involvement of RNA" CELL, vol. 86, 1996, pages 709-718, XP002097749 NA US see the whole document	1
X/	WO 95 15373 A (UNIV MCGILL ;SZYF MOSHE (CA)) 8 June 1995 see claims 12,13	1

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 98/01059

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:

See continuation sheet

2. ☒ Claims Nos.: 19:22 (in part)  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
Said claims relate to antagonists, inhibitors or small molecules without giving a true technical characterization of the claimed matter. In consequence, the scope of said claims is ambiguous and, moreover, their subject-matter is vague and not sufficiently disclosed.
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Although claims 4-6,8,9,12,14,20-25,27,28 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition (applies where the subject-matter of said claims relates to an vivo treatment).

Although claim 29 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 98/01059

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9515373 A	08-06-1995	CA 2110213 A	31-05-1995
		AU 1061395 A	19-06-1995
		CA 2177031 A	08-06-1995
		EP 0734436 A	02-10-1996
		EP 0889122 A	07-01-1999
		JP 9506253 T	24-06-1997
<hr/>			

## PATENT COOPERATION TREATY

## PCT

REC'D 11 FEB 2000

WIPO

PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 1770-183PCT	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/CA98/01059	International filing date (day/month/year) 12/11/1998	Priority date (day/month/year) 12/11/1997
International Patent Classification (IPC) or national classification and IPC C12N15/52		
Applicant McGILL UNIVERSITY et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 8 sheets, including this cover sheet.

- ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 1 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☒ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand  07/06/1999	Date of completion of this report  10.02.00
Name and mailing address of the international preliminary examining authority:  European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas	Authorized officer  Eenen 1



# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/CA98/01059

## I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

### Description, pages:

1-44 as originally filed

### Claims, No.:

9-29 as originally filed

1-8 as received on 09/12/1999 with letter of 09/12/1999

### Drawings, sheets:

1/36-36/36 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

## II. Priority

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:
- ☐ copy of the earlier application whose priority has been claimed.
  - ☐ translation of the earlier application whose priority has been claimed.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/CA98/01059

2. ☐ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:

**see separate sheet**

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 19, in part: 22; 4-6 (in part), 8,9,12,14,20-25,27,28; with respect to industrial applicability.

because:

- ☒ the said international application, or the said claims Nos. 4-6 (in part), 8,9,12,14,20-25,27,28 relate to the following subject matter which does not require an international preliminary examination (*specify*):

**see separate sheet**

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☒ no international search report has been established for the said claims Nos. 19, in part: 22.



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/CA98/01059

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Yes:	Claims	4-9,12-18,20,21,22,23-29
	No:	Claims	1-3,10,11
Inventive step (IS)	Yes:	Claims	4-9,12-18,20,21,22,23-29
	No:	Claims	1-3,10,11
Industrial applicability (IA)	Yes:	Claims	1-3; in part: 4-6; 7,10,11,13,15-18,26,29
	No:	Claims	

**2. Citations and explanations**

**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

**see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/CA98/01059

**Re Item II**

**Priority**

The present international application relates to the following priority documents:

- CA 2 220 805 (12 Nov 1997) (**prio 1**),
- CA 2 230 991 (11 May 1998) (**prio 2**).

Prio 1 relates to DNA methylase, however no corresponding sequences are disclosed.

Prio 2 relates to human demethylase cDNA and the deduced amino acid sequence (Fig. 4), however said sequence corresponds only to part of the sequences of SEQ ID NO 1 and 2 (Fig. 9) of present international application.

In fact, said deduced amino acid sequence corresponds to Fig. 8b of present international application.

Moreover, for SEQ ID Nos 3,4,5,6,7,8 no basis may be found in prio 2.

In consequence, the valid filing date of claims 1-3 is the 12 Nov 1998 (i.e. International filing date of PCT/CA98/01059), since said claims do not enjoy a valid priority right (Art. 8, PCT).

This also applies for the claims referring to or depending on said claims 2 and 3.

**Re Item III**

**Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

Claims 4-6,8,9,12,14,20-25,27,28 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

**Re Item V**

**Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1). The present international application relates to a mammalian DNA demethylase. The corresponding DNA and amino acid sequences are given.

2.1). Reference is made to the following document:

**D1:** MOLECULAR AND CELLULAR BIOLOGY, vol. 18, pp. 6538-6547,  
November 11, 1998

**D2:** nucleotide accession number AF072242; 28 Oct 1998

**D3:** nucleotide accession number AF072243; 28 Oct 1998

**D4 :** nucleotide accession number AF072247, 28 Oct 1998

**D5:** nucleotide accession number AF072248, 28 Oct 1998

Documents D2 to D5 are not cited within the International Search Report, however they are referred within D1.

3). Apparently, the exact publishing date of D1 may be November 11, 1998. In order to avoid any ambiguity, the IPEA prefers also referring to D2 to D5 for establishing novelty and inventive step.

3.1). D1 relates to the cloning and expression of methyl-CpG binding domain (MBD) containing proteins MBD2 to MBD4. In particular, MBD2 and MBD3 were expressed in bacterial cells, and as GFP-MBD fusion proteins under the control of the cytomegalovirus promoter in mammalian cells. The DNA binding properties to methylated and non-methylated DNA of the recombinant MDB proteins are studied. However, D1 is silent with respect to any demethylase activity of said proteins.

3.2.1). <sup>57</sup> SEQ ID No 1 (present application) has 100% identity in 1804 bp overlap with the sequence of D3 relating to Mus musculus methyl-CpG binding protein MBD2 mRNA (AF072243). The amino acid sequence deduced from AF072243: SPTREMBL:Q9Z2E1

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/CA98/01059

being also given in D3 has 100% identity in 414 amino acid (aa) overlap with present SEQ ID No 6 (Fig. 9K).

3.2.2). SEQ ID No 3 (present application) has 100% identity in 1589 bp overlap with the sequence of D5 relating to *Mus musculus* methyl-CpG binding protein MBD3 mRNA (AF072248). The amino acid sequence deduced from AF072248: SPTREMBL:Q9Z2D8 being also given in D5 has 100% identity in 285 aa overlap with present SEQ ID No 8 (Fig. 9N).

3.2.3). SEQ ID No 5 (present application) has 100% identity in 1966 bp overlap with the sequence of D2 relating to *Homo sapiens* methyl-CpG binding protein MBD2 mRNA (AF072242). The amino acid sequence deduced from AF072242: SPTREMBLNEW:AAC68871 being also given in D2 has 100% identity in 411 aa overlap with present SEQ ID NO 2 (Fig. 9C).

3.2.4). SEQ ID No 7 (present application) has 100% identity in 2392 bp overlap with the sequence of D4 relating to *Homo sapiens* methyl-CpG binding protein MBD3 mRNA (AF072247). The amino acid sequence deduced from AF072247: SPTREMBL:O95983 being also given in D4 has 100% identity in 291 aa overlap with present SEQ ID NO 4 (Fig. 9F).

4.1). Having regard to the above mentions, claims 1-3,10,11, do not meet the requirements of Art. 33 (2) PCT for the following reasons:

Although D1 to D5 do not refer to any DNA demethylase activity of the described MBD proteins, the sequences encoding said MBD proteins and their deduced amino acid sequences are absolutely identical with the sequences given within SEQ ID Nos 1-8 of the present application (see above).

In consequence, the technical features given within claims 1-3 are not distinguishable from the technical features disclosed in D1-D5.

Furthermore, the DNA demethylase activity of said proteins is considered to be a functional feature relating to a property inherent of said MBD proteins.

D1 is also novelty destroying for claims 10,11, since their scope is embraced by the disclosures made in D1.

4.2). Claims 4-9,12-18,20,21, in part 22, 23-29 meet the requirements of Art. 33 (2) and

(3) since their subject-matter was neither described nor suggested in the available prior art.

5.1). For the assessment of the present claims 4-6,8,9,12,14,20-25,27,28 (in so far as the relate to *in vivo* subject-matter) on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

5.2). The industrial applicability of claims 1-3; in part: 4-6; 7,10,11,13,15-18,26,29 is acknowledged (Art. 33 (4) PCT).

#### **Re Item VIII**

##### **Certain observations on the international application**

Fig. 9A-9B (SEQ ID No:1) relate to human DNA demethylase 1 cDNA, however this sequence is contained in SEQ ID No 5.

Fig. 9D-9E (SEQ ID No:3) relate to human DNA demethylase 2 cDNA, however this sequence is contained in SEQ ID No 7.

Fig. 9I-9J (SEQ ID No:5) relate to mouse DNA demethylase 1 cDNA, however this sequence is contained in SEQ ID No 1.

Fig. 9L-9M (SEQ ID No:7) relate to mouse DNA demethylase 2 cDNA, however this sequence is contained in SEQ ID No 3.

Apparently, there exists an inconsistency not allowable under Art. 6 PCT.

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

09/554414

FEB 17 2000

PCT

A.M.

3	9	12	1	2	3	4	5
---	---	----	---	---	---	---	---

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT

(PCT Rule 71.1)

To:

COTE, F.  
SWABEY OGILVY RENAULT  
1981 McGill College Avenue  
Suite 1600  
Montréal, Québec H3A 2Y3  
CANADA

Date of mailing  
(day/month/year)

1 0. 02. 00

Applicant's or agent's file reference  
1770-183PCT

## IMPORTANT NOTIFICATION

International application No.  
PCT/CA98/01059

International filing date (day/month/year)  
12/11/1998

Priority date (day/month/year)  
12/11/1997

Applicant

McGILL UNIVERSITY et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.


## 4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/



European Patent Office - P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk - Pays Bas  
Tel. +31 70 340 - 2040 Tx: 31 651 epo nl  
Fax: +31 70 340 - 3016

Authorized officer

Sinanovic, E

Tel. +31 70 340-3596



## PATENT COOPERATION TREATY

PCT

09/554414

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)



Applicant's or agent's file reference 1770-183PCT		<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/CA98/01059	International filing date (day/month/year) 12/11/1998	Priority date (day/month/year) 12/11/1997	
International Patent Classification (IPC) or national classification and IPC C12N15/52			
Applicant McGILL UNIVERSITY et al.			

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 8 sheets, including this cover sheet.
  - ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 1 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☒ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand  07/06/1999	Date of completion of this report  10.02.00
Name and mailing address of the international preliminary examining authority:   European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016	Authorized officer  Espen, J  Telephone No. +31 70 340 2625  

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/CA98/01059

**I. Basis of the report**

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

**Description, pages:**

1-44 as originally filed

**Claims, No.:**

9-29 as originally filed

1-8 as received on 09/12/1999 with letter of 09/12/1999

**Drawings, sheets:**

1/36-36/36 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:  
☐ the claims, Nos.:  
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

**II. Priority**

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:
- ☐ copy of the earlier application whose priority has been claimed.
- ☐ translation of the earlier application whose priority has been claimed.



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/CA98/01059

2. ☐ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:

**see separate sheet**

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 19, in part: 22; 4-6 (in part), 8,9,12,14,20-25,27,28; with respect to industrial applicability.

because:

- ☒ the said international application, or the said claims Nos. 4-6 (in part), 8,9,12,14,20-25,27,28 relate to the following subject matter which does not require an international preliminary examination (*specify*):

**see separate sheet**

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

- ☒ no international search report has been established for the said claims Nos. 19, in part: 22.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/CA98/01059

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Yes:	Claims	4-9,12-18,20,21,22,23-29
	No:	Claims	1-3,10,11
Inventive step (IS)	Yes:	Claims	4-9,12-18,20,21,22,23-29
	No:	Claims	1-3,10,11
Industrial applicability (IA)	Yes:	Claims	1-3; in part: 4-6; 7,10,11,13,15-18,26,29
	No:	Claims	

**2. Citations and explanations**

**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

**see separate sheet**

**Re Item II**

**Priority**

The present international application relates to the following priority documents:

- CA 2 220 805 (12 Nov 1997) (**prio 1**),
- CA 2 230 991 (11 May 1998) (**prio 2**).

Prio 1 relates to DNA methylase, however no corresponding sequences are disclosed.

Prio 2 relates to human demethylase cDNA and the deduced amino acid sequence (Fig. 4), however said sequence corresponds only to part of the sequences of SEQ ID NO 1 and 2 (Fig. 9) of present international application.

In fact, said deduced amino acid sequence corresponds to Fig. 8b of present international application.

Moreover, for SEQ ID Nos 3,4,5,6,7,8 no basis may be found in prio 2.

In consequence, the valid filing date of claims 1-3 is the 12 Nov 1998 (i.e. International filing date of PCT/CA98/01059), since said claims do not enjoy a valid priority right (Art. 8, PCT).

This also applies for the claims referring to or depending on said claims 2 and 3.

**Re Item III**

**Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

Claims 4-6,8,9,12,14,20-25,27,28 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

**Re Item V**

**Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1). The present international application relates to a mammalian DNA demethylase. The corresponding DNA and amino acid sequences are given.

2.1). Reference is made to the following document:

**D1:** MOLECULAR AND CELLULAR BIOLOGY, vol. 18, pp. 6538-6547,  
November 11, 1998

**D2:** nucleotide accession number AF072242; 28 Oct 1998

**D3:** nucleotide accession number AF072243; 28 Oct 1998

**D4 :** nucleotide accession number AF072247, 28 Oct 1998

**D5:** nucleotide accession number AF072248, 28 Oct 1998

Documents D2 to D5 are not cited within the International Search Report, however they are referred within D1.

3). Apparently, the exact publishing date of D1 may be November 11, 1998. In order to avoid any ambiguity, the IPEA prefers also referring to D2 to D5 for establishing novelty and inventive step.

3.1). D1 relates to the cloning and expression of methyl-CpG binding domain (MBD) containing proteins MBD2 to MBD4. In particular, MBD2 and MBD3 were expressed in bacterial cells, and as GFP-MBD fusion proteins under the control of the cytomegalovirus promoter in mammalian cells. The DNA binding properties to methylated and non-methylated DNA of the recombinant MDB proteins are studied. However, D1 is silent with respect to any demethylase activity of said proteins.

3.2.1). SEQ ID No 1 (present application) has 100% identity in 1804 bp overlap with the sequence of D3 relating to Mus musculus methyl-CpG binding protein MBD2 mRNA (AF072243). The amino acid sequence deduced from AF072243: SPTREMBL:Q9Z2E1

being also given in D3 has 100% identity in 414 amino acid (aa) overlap with present SEQ ID No 6 (Fig. 9K).

3.2.2). SEQ ID No 3 (present application) has 100% identity in 1589 bp overlap with the sequence of D5 relating to *Mus musculus* methyl-CpG binding protein MBD3 mRNA (AF072248). The amino acid sequence deduced from AF072248: SPTREMBL:Q9Z2D8 being also given in D5 has 100% identity in 285 aa overlap with present SEQ ID No 8 (Fig. 9N).

3.2.3). SEQ ID No 5 (present application) has 100% identity in 1966 bp overlap with the sequence of D2 relating to *Homo sapiens* methyl-CpG binding protein MBD2 mRNA (AF072242). The amino acid sequence deduced from AF072242: SPTREMBLNEW:AAC68871 being also given in D2 has 100% identity in 411 aa overlap with present SEQ ID NO 2 (Fig. 9C).

3.2.4). SEQ ID No 7 (present application) has 100% identity in 2392 bp overlap with the sequence of D4 relating to *Homo sapiens* methyl-CpG binding protein MBD3 mRNA (AF072247). The amino acid sequence deduced from AF072247: SPTREMBL:O95983 being also given in D4 has 100% identity in 291 aa overlap with present SEQ ID NO 4 (Fig. 9F).

4.1). Having regard to the above mentions, claims 1-3,10,11, do not meet the requirements of Art. 33 (2) PCT for the following reasons:

Although D1 to D5 do not refer to any DNA demethylase activity of the described MBD proteins, the sequences encoding said MBD proteins and their deduced amino acid sequences are absolutely identical with the sequences given within SEQ ID Nos 1-8 of the present application (see above).

In consequence, the technical features given within claims 1-3 are not distinguishable from the technical features disclosed in D1-D5.

Furthermore, the DNA demethylase activity of said proteins is considered to be a functional feature relating to a property inherent of said MBD proteins.

D1 is also novelty destroying for claims 10,11, since their scope is embraced by the disclosures made in D1.

4.2). Claims 4-9,12-18,20,21, in part 22, 23-29 meet the requirements of Art. 33 (2) and

(3) since their subject-matter was neither described nor suggested in the available prior art.

5.1). For the assessment of the present claims 4-6,8,9,12,14,20-25,27,28 (in so far as they relate to *in vivo* subject-matter) on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

5.2). The industrial applicability of claims 1-3, in part: 4-6; 7,10,11,13,15-18,26,29 is acknowledged (Art. 33 (4) PCT).

### **Re Item VIII**

#### **Certain observations on the international application**

Fig. 9A-9B (SEQ ID No:1) relate to human DNA demethylase 1 cDNA, however this sequence is contained in SEQ ID No 5.

Fig. 9D-9E (SEQ ID No:3) relate to human DNA demethylase 2 cDNA, however this sequence is contained in SEQ ID No 7.

Fig. 9I-9J (SEQ ID No:5) relate to mouse DNA demethylase 1 cDNA, however this sequence is contained in SEQ ID No 1.

Fig. 9L-9M (SEQ ID No:7) relate to mouse DNA demethylase 2 cDNA, however this sequence is contained in SEQ ID No 3.

Apparently, there exists an inconsistency not allowable under Art. 6 PCT.

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>1770-183PCT</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/CA 98/01059</b>	International filing date (day/month/year) <b>12/11/1998</b>	(Earliest) Priority Date (day/month/year) <b>12/11/1997</b>
Applicant <b>McGILL UNIVERSITY et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.



It is also accompanied by a copy of each prior art document cited in this report.

## 1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.



the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing:



contained in the international application in written form.



filed together with the international application in computer readable form.



furnished subsequently to this Authority in written form.



furnished subsequently to this Authority in computer readable form.



the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.



the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,



the text is approved as submitted by the applicant.



the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,



the text is approved as submitted by the applicant.



the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.



as suggested by the applicant.



because the applicant failed to suggest a figure.



because this figure better characterizes the invention.



None of the figures.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 98/ 01059

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:

See continuation sheet

2. ☒ Claims Nos.: 19;22 (in part)  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
Said claims relate to antagonists, inhibitors or small molecules without giving a true technical characterization of the claimed matter. In consequence, the scope of said claims is ambiguous and, moreover, their subject-matter is vague and not sufficiently disclosed.
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Remark: Although claims 4-6,8,9,12,14,20-25,27,28 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition (applies where the subject-matter of said claims relates to an vivo treatment). Although claim 29 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Although claims 4-6,8,9,12,14,20-25,27,28 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition (applies where the subject-matter of said claims relates to an vivo treatment).  
Although claim 29 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 98/01059

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/52 C12N9/00 A61K38/43 C07K16/40 C12N15/11  
 A61K48/00 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	BHATTACHARYA SK ET AL: "A mammalian protein with specific demethylase activity for mCpG DNA" NATURE, vol. 397, 18 February 1999, pages 579-583, XP002097746 LONDON GB	
P,X	<p>----</p> <p>HENDRICH B ET AL: "Identification and characterization of a family of mammalian methyl-CpG binding proteins." MOLECULAR AND CELLULAR BIOLOGY, (1998 NOV) 18 (11) 6538-47. JOURNAL CODE: NGY. ISSN: 0270-7306., XP002097747 United States see the whole document</p> <p>----</p> <p>-/--</p>	1-3

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

24 March 1999

Date of mailing of the international search report

08/04/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Espen, J

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>SZYF M. ET AL.: "Mammalian cells contain a general (CpG) DNA demethylating activity"</p> <p>MOLECULAR BIOLOGY OF THE CELL, vol. 4, October 1993, page 74A</p> <p>XP002087767</p> <p>* abstract 426 *</p> <p>---</p>	1
X	<p>SZYF M ET AL: "Ras induces a general DNA demethylation activity in mouse embryonal P19 cells."</p> <p>J BIOL CHEM, MAY 26 1995, 270 (21)</p> <p>P12690-6, XP002087765</p> <p>UNITED STATES</p> <p>see the whole document</p> <p>---</p>	1
X	<p>SZYF M: "DNA methylation properties: consequences for pharmacology."</p> <p>TRENDS PHARMACOL SCI, JUL 1994, 15 (7)</p> <p>P233-8, XP002087766</p> <p>ENGLAND</p> <p>see page 234, right-hand column; figures 1,2</p> <p>---</p>	1
X	<p>WEISS A ET AL: "The role of DNA demethylation during development."</p> <p>GENES TO CELLS, (1997 AUG) 2 (8) 481-6.</p> <p>REF: 35 JOURNAL CODE: CUF. ISSN: 1356-9597., XP002097748</p> <p>ENGLAND: United Kingdom</p> <p>see figures 3,4</p> <p>---</p>	1
X	<p>WEISS A ET AL: "DNA demethylation in vitro: involvement of RNA"</p> <p>CELL, vol. 86, 1996, pages 709-718, XP002097749</p> <p>NA US</p> <p>see the whole document</p> <p>---</p>	1
X	<p>WO 95 15373 A (UNIV MCGILL ;SZYF MOSHE (CA)) 8 June 1995</p> <p>see claims 12,13</p> <p>-----</p>	1

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 98/01059

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9515373 A	08-06-1995	CA 2110213 A	31-05-1995
		AU 1061395 A	19-06-1995
		CA 2177031 A	08-06-1995
		EP 0734436 A	02-10-1996
		EP 0889122 A	07-01-1999
		JP 9506253 T	24-06-1997
-----			

## PATENT COOPERATION TREATY

REC'D 11 FEB 2000

## PCT

WIPO PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)



Applicant's or agent's file reference 1770-183PCT	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/CA98/01059	International filing date (day/month/year) 12/11/1998	Priority date (day/month/year) 12/11/1997
International Patent Classification (IPC) or national classification and IPC C12N15/52		
Applicant McGILL UNIVERSITY et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 8 sheets, including this cover sheet.
- ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 1 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☒ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand  07/06/1999	Date of completion of this report  10.02.00
Name and mailing address of the international preliminary examining authority:  European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016	Authorized officer  Espen, J  Telephone No. +31 70 340 2625 

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/CA98/01059

**I. Basis of the report**

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

**Description, pages:**

1-44 as originally filed

**Claims, No.:**

9-29 as originally filed

1-8 as received on 09/12/1999 with letter of 09/12/1999

**Drawings, sheets:**

1/36-36/36 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:  
☐ the claims, Nos.:  
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

**II. Priority**

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:
- ☐ copy of the earlier application whose priority has been claimed.
- ☐ translation of the earlier application whose priority has been claimed.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/CA98/01059

2. ☐ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:

**see separate sheet**

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 19, in part: 22; 4-6 (in part), 8,9,12,14,20-25,27,28; with respect to industrial applicability.

because:

- ☒ the said international application, or the said claims Nos. 4-6 (in part), 8,9,12,14,20-25,27,28 relate to the following subject matter which does not require an international preliminary examination (*specify*):

**see separate sheet**

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☒ no international search report has been established for the said claims Nos. 19, in part: 22.



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/CA98/01059

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Yes:	Claims	4-9,12-18,20,21,22,23-29
	No:	Claims	1-3,10,11
Inventive step (IS)	Yes:	Claims	4-9,12-18,20,21,22,23-29
	No:	Claims	1-3,10,11
Industrial applicability (IA)	Yes:	Claims	1-3; in part: 4-6; 7,10,11,13,15-18,26,29
	No:	Claims	

**2. Citations and explanations**

**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

**see separate sheet**

**Re Item II**

**Priority**

The present international application relates to the following priority documents:

- CA 2 220 805 (12 Nov 1997) (**prio 1**),
- CA 2 230 991 (11 May 1998) (**prio 2**).

Prio 1 relates to DNA methylase, however no corresponding sequences are disclosed.

Prio 2 relates to human demethylase cDNA and the deduced amino acid sequence (Fig. 4), however said sequence corresponds only to part of the sequences of SEQ ID NO 1 and 2 (Fig. 9) of present international application.

In fact, said deduced amino acid sequence corresponds to Fig. 8b of present international application.

Moreover, for SEQ ID Nos 3,4,5,6,7,8 no basis may be found in prio 2.

In consequence, the valid filing date of claims 1-3 is the 12 Nov 1998 (i.e. International filing date of PCT/CA98/01059), since said claims do not enjoy a valid priority right (Art. 8, PCT).

This also applies for the claims referring to or depending on said claims 2 and 3.

**Re Item III**

**Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

Claims 4-6,8,9,12,14,20-25,27,28 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

**Re Item V**

**Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1). The present international application relates to a mammalian DNA demethylase. The corresponding DNA and amino acid sequences are given.

2.1). Reference is made to the following document:

**D1:** MOLECULAR AND CELLULAR BIOLOGY, vol. 18, pp. 6538-6547,  
November 11, 1998

**D2:** nucleotide accession number AF072242; 28 Oct 1998

**D3:** nucleotide accession number AF072243; 28 Oct 1998

**D4 :** nucleotide accession number AF072247, 28 Oct 1998

**D5:** nucleotide accession number AF072248, 28 Oct 1998

Documents D2 to D5 are not cited within the International Search Report, however they are referred within D1.

3). Apparently, the exact publishing date of D1 may be November 11, 1998. In order to avoid any ambiguity, the IPEA prefers also referring to D2 to D5 for establishing novelty and inventive step.

3.1). D1 relates to the cloning and expression of methyl-CpG binding domain (MBD) containing proteins MBD2 to MBD4. In particular, MBD2 and MBD3 were expressed in bacterial cells, and as GFP-MBD fusion proteins under the control of the cytomegalovirus promoter in mammalian cells. The DNA binding properties to methylated and non-methylated DNA of the recombinant MDB proteins are studied. However, D1 is silent with respect to any demethylase activity of said proteins.

3.2.1). SEQ ID No 1 (present application) has 100% identity in 1804 bp overlap with the sequence of D3 relating to Mus musculus methyl-CpG binding protein MBD2 mRNA (AF072243). The amino acid sequence deduced from AF072243: SPTREMBL:Q9Z2E1

being also given in D3 has 100% identity in 414 amino acid (aa) overlap with present SEQ ID No 6 (Fig. 9K).

3.2.2). SEQ ID No 3 (present application) has 100% identity in 1589 bp overlap with the sequence of D5 relating to *Mus musculus* methyl-CpG binding protein MBD3 mRNA (AF072248). The amino acid sequence deduced from AF072248: SPTREMBL:Q9Z2D8 being also given in D5 has 100% identity in 285 aa overlap with present SEQ ID No 8 (Fig. 9N).

3.2.3). SEQ ID No 5 (present application) has 100% identity in 1966 bp overlap with the sequence of D2 relating to *Homo sapiens* methyl-CpG binding protein MBD2 mRNA (AF072242). The amino acid sequence deduced from AF072242: SPTREMBLNEW:AAC68871 being also given in D2 has 100% identity in 411 aa overlap with present SEQ ID NO 2 (Fig. 9C).

3.2.4). SEQ ID No 7 (present application) has 100% identity in 2392 bp overlap with the sequence of D4 relating to *Homo sapiens* methyl-CpG binding protein MBD3 mRNA (AF072247). The amino acid sequence deduced from AF072247: SPTREMBL:O95983 being also given in D4 has 100% identity in 291 aa overlap with present SEQ ID NO 4 (Fig. 9F).

4.1). Having regard to the above mentions, claims 1-3,10,11, do not meet the requirements of Art. 33 (2) PCT for the following reasons:

Although D1 to D5 do not refer to any DNA demethylase activity of the described MBD proteins, the sequences encoding said MBD proteins and their deduced amino acid sequences are absolutely identical with the sequences given within SEQ ID Nos 1-8 of the present application (see above).

In consequence, the technical features given within claims 1-3 are not distinguishable from the technical features disclosed in D1-D5.

Furthermore, the DNA demethylase activity of said proteins is considered to be a functional feature relating to a property inherent of said MBD proteins.

D1 is also novelty destroying for claims 10,11, since their scope is embraced by the disclosures made in D1.

4.2). Claims 4-9,12-18,20,21, in part 22, 23-29 meet the requirements of Art. 33 (2) and

(3) since their subject-matter was neither described nor suggested in the available prior art.

5.1). For the assessment of the present claims 4-6,8,9,12,14,20-25,27,28 (in so far as they relate to *in vivo* subject-matter) on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

5.2). The industrial applicability of claims 1-3, in part: 4-6; 7,10,11,13,15-18,26,29 is acknowledged (Art. 33 (4) PCT).

#### **Re Item VIII**

##### **Certain observations on the international application**

Fig. 9A-9B (SEQ ID No:1) relate to human DNA demethylase 1 cDNA, however this sequence is contained in SEQ ID No 5.

Fig. 9D-9E (SEQ ID No:3) relate to human DNA demethylase 2 cDNA, however this sequence is contained in SEQ ID No 7.

Fig. 9I-9J (SEQ ID No:5) relate to mouse DNA demethylase 1 cDNA, however this sequence is contained in SEQ ID No 1.

Fig. 9L-9M (SEQ ID No:7) relate to mouse DNA demethylase 2 cDNA, however this sequence is contained in SEQ ID No 3.

Apparently, there exists an inconsistency not allowable under Art. 6 PCT.